{"id":4611,"date":"2025-09-27T15:39:48","date_gmt":"2025-09-27T12:39:48","guid":{"rendered":"https:\/\/dmdwarrior.com\/?page_id=4611"},"modified":"2026-06-30T18:14:04","modified_gmt":"2026-06-30T15:14:04","slug":"dmd-therapies","status":"publish","type":"page","link":"https:\/\/dmdwarrior.com\/pt\/dmd-therapies\/","title":{"rendered":"Terapias para Duchenne (Lista de todas as pesquisas)"},"content":{"rendered":"<div id=\"tdi_1\" class=\"tdc-zone\"><div class=\"tdc_zone tdi_2  wpb_row td-pb-row\"  >\n<style scoped>\n\/* custom css - generated by TagDiv Composer *\/\n\n\/* custom css - generated by TagDiv Composer *\/\n.tdi_2{\r\n                    min-height: 0;\r\n                }\n<\/style><div id=\"tdi_3\" class=\"tdc-row stretch_row_1400 td-stretch-content\"><div class=\"vc_row tdi_4  wpb_row td-pb-row tdc-element-style\" >\n<style scoped>\n\/* custom css - generated by TagDiv Composer *\/\n\n\/* custom css - generated by TagDiv Composer *\/\n.tdi_4,\r\n                .tdi_4 .tdc-columns{\r\n                    min-height: 0;\r\n                }.tdi_4 > .td-element-style:after{\r\n                    content: '' !important;\r\n                    width: 100% !important;\r\n                    height: 100% !important;\r\n                    position: absolute !important;\r\n                    top: 0 !important;\r\n                    left: 0 !important;\r\n                    z-index: 0 !important;\r\n                    display: block !important;\r\n                    background: -webkit-linear-gradient(0deg,rgba(0,0,0,0),rgba(0,0,0,0) 73%,rgba(0,0,0,0.6) 84%,rgba(0,0,0,0.6));background: linear-gradient(0deg,rgba(0,0,0,0),rgba(0,0,0,0) 73%,rgba(0,0,0,0.6) 84%,rgba(0,0,0,0.6));\r\n                }.tdi_4,\r\n\t\t\t\t.tdi_4 .tdc-columns{\r\n\t\t\t\t    display: block;\r\n\t\t\t\t}.tdi_4 .tdc-columns{\r\n\t\t\t\t    width: 100%;\r\n\t\t\t\t}.tdi_4:before,\r\n\t\t\t\t.tdi_4:after{\r\n\t\t\t\t    display: table;\r\n\t\t\t\t}@media (min-width: 768px) {\r\n\t                .tdi_4 {\r\n\t                    margin-left: -50px;\r\n\t                    margin-right: -50px;\r\n\t                }\r\n\t                .tdi_4 .tdc-row-video-background-error,\r\n\t                .tdi_4 > .vc_column,\r\n\t                .tdi_4 > .tdc-columns > .vc_column {\r\n\t                    padding-left: 50px;\r\n\t                    padding-right: 50px;\r\n\t                }\r\n                }\n\n\/* landscape *\/\n@media (min-width: 1019px) and (max-width: 1140px){\n@media (min-width: 768px) {\r\n\t                .tdi_4 {\r\n\t                    margin-left: -25px;\r\n\t                    margin-right: -25px;\r\n\t                }\r\n\t                .tdi_4 .tdc-row-video-background-error,\r\n\t                .tdi_4 > .vc_column,\r\n\t                .tdi_4 > .tdc-columns > .vc_column {\r\n\t                    padding-left: 25px;\r\n\t                    padding-right: 25px;\r\n\t                }\r\n                }\n}\n\n\/* portrait *\/\n@media (min-width: 768px) and (max-width: 1018px){\n@media (min-width: 768px) {\r\n\t                .tdi_4 {\r\n\t                    margin-left: -15px;\r\n\t                    margin-right: -15px;\r\n\t                }\r\n\t                .tdi_4 .tdc-row-video-background-error,\r\n\t                .tdi_4 > .vc_column,\r\n\t                .tdi_4 > .tdc-columns > .vc_column {\r\n\t                    padding-left: 15px;\r\n\t                    padding-right: 15px;\r\n\t                }\r\n                }\n}\n\/* inline tdc_css att - generated by TagDiv Composer *\/\n\n.tdi_4{\npadding-top:240px !important;\npadding-bottom:60px !important;\nbox-shadow:0 20px 100px #000000 !important;\nz-index:2 !important;\nposition:relative;\n}\n\n.tdi_4 .td_block_wrap{ text-align:left }\n\n\/* landscape *\/\n@media (min-width: 1019px) and (max-width: 1140px)\n{\n.tdi_4{\npadding-top:220px !important;\npadding-bottom:50px !important;\nbox-shadow:0 20px 100px #000000 !important;\n}\n}\n\n\/* portrait *\/\n@media (min-width: 768px) and (max-width: 1018px)\n{\n.tdi_4{\npadding-top:180px !important;\npadding-right:5px !important;\npadding-bottom:40px !important;\npadding-left:5px !important;\nbox-shadow:0 20px 100px #000000 !important;\n}\n}\n\n\/* phone *\/\n@media (max-width: 767px)\n{\n.tdi_4{\npadding-top:60px !important;\npadding-bottom:40px !important;\nbox-shadow:0 20px 100px #000000 !important;\nposition:relative;\n}\n}\n\n<\/style>\n<div class=\"tdi_3_rand_style td-element-style\" ><div class=\"td-element-style-before\"><style>\n\/* custom css - generated by TagDiv Composer *\/\n\n.tdi_3_rand_style > .td-element-style-before {\ncontent:'' !important;\nwidth:100% !important;\nheight:100% !important;\nposition:absolute !important;\ntop:0 !important;\nleft:0 !important;\ndisplay:block !important;\nz-index:0 !important;\nborder-color:#000000 !important;\nbackground-image:url(\"https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/09\/cure-of-duchenne-laboratory.jpg\") !important;\nbackground-position:center center !important;\nborder-style:solid !important;\nborder-width:0 !important;\nbackground-size:cover !important;\n}\n\n\/* phone *\/\n@media (max-width: 767px)\n{\n.tdi_3_rand_style > .td-element-style-before{\ncontent:'' !important;\nwidth:100% !important;\nheight:100% !important;\nposition:absolute !important;\ntop:0 !important;\nleft:0 !important;\ndisplay:block !important;\nz-index:0 !important;\nopacity:0.9 !important;\n}\n}\n<\/style><\/div><style>\n\/* custom css - generated by TagDiv Composer *\/\n\n.tdi_3_rand_style{\nbackground-color:#181923 !important;\n}\n \n.tdi_3_rand_style::after {\ncontent:'' !important;\nwidth:100% !important;\nheight:100% !important;\nposition:absolute !important;\ntop:0 !important;\nleft:0 !important;\nz-index:0 !important;\ndisplay:block !important;\nbackground: rgba(0,0,0,0.68) !important;\n}\n<\/style><\/div><div class=\"vc_column tdi_6  wpb_column vc_column_container tdc-column td-pb-span12\">\n<style scoped>\n\/* custom css - generated by TagDiv Composer *\/\n\n\/* custom css - generated by TagDiv Composer *\/\n.tdi_6{\r\n                    vertical-align: baseline;\r\n                }.tdi_6 > .wpb_wrapper,\r\n\t\t\t\t.tdi_6 > .wpb_wrapper > .tdc-elements{\r\n\t\t\t\t    display: block;\r\n\t\t\t\t}.tdi_6 > .wpb_wrapper > .tdc-elements{\r\n\t\t\t\t    width: 100%;\r\n\t\t\t\t}.tdi_6 > .wpb_wrapper > .vc_row_inner{\r\n\t\t\t\t    width: auto;\r\n\t\t\t\t}.tdi_6 > .wpb_wrapper{\r\n\t\t\t\t    width: auto;\r\n\t\t\t\t    height: auto;\r\n\t\t\t\t}\n<\/style><div class=\"wpb_wrapper\" ><div class=\"vc_row_inner tdi_8 td-text-animation td-left-animation td-order-1 vc_row vc_inner wpb_row td-pb-row\" >\n<style scoped>\n\/* custom css - generated by TagDiv Composer *\/\n\n\/* custom css - generated by TagDiv Composer *\/\n.tdi_8{\r\n                    position: relative !important;\r\n                    top: 0;\r\n                    transform: none;\r\n                    -webkit-transform: none;\r\n                }.tdi_8,\r\n\t\t\t\t.tdi_8 .tdc-inner-columns{\r\n\t\t\t\t    display: flex;\r\n\t\t\t\t\r\n\t\t\t\t    flex-direction: row;\r\n\t\t\t\t\r\n\t\t\t\t    flex-wrap: nowrap;\r\n\t\t\t\t\r\n\t\t\t\t    justify-content: flex-start;\r\n\t\t\t\t\r\n\t\t\t\t    align-items: center;\r\n\t\t\t\t}.tdi_8 .tdc-inner-columns{\r\n\t\t\t\t    width: 100%;\r\n\t\t\t\t}@media (min-width: 768px) {\r\n\t                .tdi_8 {\r\n\t                    margin-left: -0px;\r\n\t                    margin-right: -0px;\r\n\t                }\r\n\t                .tdi_8 > .vc_column_inner,\r\n\t                .tdi_8 > .tdc-inner-columns > .vc_column_inner {\r\n\t                    padding-left: 0px;\r\n\t                    padding-right: 0px;\r\n\t                }\r\n                }\n\n\/* phone *\/\n@media (max-width: 767px){\n.tdi_8,\r\n\t\t\t\t.tdi_8 .tdc-inner-columns{\r\n\t\t\t\t    flex-direction: column;\r\n\t\t\t\t}\n}\n\/* inline tdc_css att - generated by TagDiv Composer *\/\n\n.tdi_8{\nmargin-bottom:80px !important;\nwidth:calc(75% + ( 0px * 2 ) ) !important;\n}\n\n.tdi_8 .td_block_wrap{ text-align:left }\n\n\/* landscape *\/\n@media (min-width: 1019px) and (max-width: 1140px)\n{\n.tdi_8{\nmargin-bottom:70px !important;\nwidth:calc(65% + ( 0px * 2 ) ) !important;\n}\n}\n\n\/* portrait *\/\n@media (min-width: 768px) and (max-width: 1018px)\n{\n.tdi_8{\nmargin-bottom:60px !important;\nwidth:calc(75% + ( 0px * 2 ) ) !important;\n}\n}\n\n\/* phone *\/\n@media (max-width: 767px)\n{\n.tdi_8{\nmargin-bottom:60px !important;\nwidth:100% !important;\n}\n}\n\n<\/style><div class=\"vc_column_inner tdi_10  wpb_column vc_column_container tdc-inner-column td-pb-span12\">\n<style scoped>\n\/* custom css - generated by TagDiv Composer *\/\n\n\/* custom css - generated by TagDiv Composer *\/\n.tdi_10{\r\n                    vertical-align: baseline;\r\n                }.tdi_10 .vc_column-inner > .wpb_wrapper,\r\n\t\t\t\t.tdi_10 .vc_column-inner > .wpb_wrapper .tdc-elements{\r\n\t\t\t\t    display: block;\r\n\t\t\t\t}.tdi_10 .vc_column-inner > .wpb_wrapper .tdc-elements{\r\n\t\t\t\t    width: 100%;\r\n\t\t\t\t}\n\/* inline tdc_css att - generated by TagDiv Composer *\/\n\n.tdi_10{\nmargin-bottom:10px !important;\n}\n\n\/* phone *\/\n@media (max-width: 767px)\n{\n.tdi_10{\nmargin-bottom:0px !important;\npadding-right:0px !important;\njustify-content:center !important;\ntext-align:center !important;\n}\n}\n\n<\/style><div class=\"vc_column-inner\"><div class=\"wpb_wrapper\" ><div class=\"tdm_block td_block_wrap tdm_block_column_title tdi_11 tdm-content-horiz-left td-pb-border-top td_block_template_1\"  data-td-block-uid=\"tdi_11\" >\n<style>\n\n\/* inline tdc_css att - generated by TagDiv Composer *\/\n\n.tdi_11{\nmargin-bottom:10px !important;\nz-index:1 !important;\n}\n\n\/* portrait *\/\n@media (min-width: 768px) and (max-width: 1018px)\n{\n.tdi_11{\nmargin-bottom:0px !important;\n}\n}\n\n<\/style>\n<style>\n\/* custom css - generated by TagDiv Composer *\/\n.tdm_block_column_title{\r\n                  margin-bottom: 0;\r\n                  display: inline-block;\r\n                  width: 100%;\r\n                }\n<\/style><div class=\"td-block-row\"><div class=\"td-block-span12 tdm-col\">\n<style>\n\/* custom css - generated by TagDiv Composer *\/\nbody .tdi_12 .tdm-title{\r\n\t\t\t\t\tcolor: #f9f8f2;\r\n\t\t\t\t}.tdi_12 .tdm-title{\r\n\t\t\t\t\tfont-family: var(--global-1) !important;font-size:64px !important;line-height:1.2 !important;font-weight:800 !important;\r\n\t\t\t\t}\n\n\/* landscape *\/\n@media (min-width: 1019px) and (max-width: 1140px){\n.tdi_12 .tdm-title{\r\n\t\t\t\t\tfont-size:60px !important;\r\n\t\t\t\t}\n}\n\n\/* portrait *\/\n@media (min-width: 768px) and (max-width: 1018px){\n.tdi_12 .tdm-title{\r\n\t\t\t\t\tfont-size:50px !important;\r\n\t\t\t\t}\n}\n\n\/* phone *\/\n@media (max-width: 767px){\n.tdi_12 .tdm-title{\r\n\t\t\t\t\tfont-size:38px !important;\r\n\t\t\t\t}\n}\n<\/style><div class=\"tds-title tds-title1 td-fix-index tdi_12 \"><h1 class=\"tdm-title tdm-title-md\">Clinical Trials for Duchenne<\/h1><\/div><\/div><\/div><\/div><div class=\"tdm_block td_block_wrap tdm_block_inline_text tdi_13 td-pb-border-top td_block_template_1\"  data-td-block-uid=\"tdi_13\" >\n<style>\n\n\/* inline tdc_css att - generated by TagDiv Composer *\/\n\n.tdi_13{\nborder-color:#000000 !important;\nwidth:90% !important;\nborder-style:solid !important;\nborder-width:0 !important;\n}\n\n\/* portrait *\/\n@media (min-width: 768px) and (max-width: 1018px)\n{\n.tdi_13{\nmargin-top:-5px !important;\nmargin-bottom:30px !important;\n}\n}\n\n\/* phone *\/\n@media (max-width: 767px)\n{\n.tdi_13{\nmargin-bottom:30px !important;\nwidth:100% !important;\n}\n}\n\n<\/style>\n<style>\n\/* custom css - generated by TagDiv Composer *\/\n.tdm_block.tdm_block_inline_text{\r\n                  margin-bottom: 0;\r\n                  vertical-align: top;\r\n                }.tdm_block.tdm_block_inline_text .tdm-descr{\r\n                  margin-bottom: 0;\r\n                  -webkit-transform: translateZ(0);\r\n                  transform: translateZ(0);\r\n                }.tdc-row-content-vert-center .tdm-inline-text-yes{\r\n                  vertical-align: middle;\r\n                }.tdc-row-content-vert-bottom .tdm-inline-text-yes{\r\n                  vertical-align: bottom;\r\n                }.tdi_13{\r\n                    text-align: left !important;\r\n                }.tdi_13 .tdm-descr{\r\n                    color: #f9f8f2;\r\n                \r\n\t\t\t\t\tfont-family: var(--global-1) !important;font-size:18px !important;line-height:1.8 !important;font-weight:400 !important;\r\n\t\t\t\t}\n\n\/* landscape *\/\n@media (min-width: 1019px) and (max-width: 1140px){\n.tdi_13 .tdm-descr{\r\n\t\t\t\t\tfont-size:17px !important;\r\n\t\t\t\t}\n}\n\n\/* portrait *\/\n@media (min-width: 768px) and (max-width: 1018px){\n.tdi_13 .tdm-descr{\r\n\t\t\t\t\tfont-size:15px !important;\r\n\t\t\t\t}\n}\n\n\/* phone *\/\n@media (max-width: 767px){\n.tdi_13 .tdm-descr{\r\n\t\t\t\t\tfont-size:20px !important;line-height:1.2 !important;font-weight:500 !important;\r\n\t\t\t\t}\n}\n<\/style><p class=\"tdm-descr\">List of all researches such as gene therapy, exon skipping, reducing inflammation and improving muscle growth & protection therapies for duchenne muscular dystrophy.<\/p><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><div id=\"tdi_14\" class=\"tdc-row\"><div class=\"vc_row tdi_15  wpb_row td-pb-row\" >\n<style scoped>\n\/* custom css - generated by TagDiv Composer *\/\n\n\/* custom css - generated by TagDiv Composer *\/\n.tdi_15,\r\n                .tdi_15 .tdc-columns{\r\n                    min-height: 0;\r\n                }.tdi_15,\r\n\t\t\t\t.tdi_15 .tdc-columns{\r\n\t\t\t\t    display: block;\r\n\t\t\t\t}.tdi_15 .tdc-columns{\r\n\t\t\t\t    width: 100%;\r\n\t\t\t\t}.tdi_15:before,\r\n\t\t\t\t.tdi_15:after{\r\n\t\t\t\t    display: table;\r\n\t\t\t\t}\n<\/style><div class=\"vc_column tdi_17  wpb_column vc_column_container tdc-column td-pb-span12\">\n<style scoped>\n\/* custom css - generated by TagDiv Composer *\/\n\n\/* custom css - generated by TagDiv Composer *\/\n.tdi_17{\r\n                    vertical-align: baseline;\r\n                }.tdi_17 > .wpb_wrapper,\r\n\t\t\t\t.tdi_17 > .wpb_wrapper > .tdc-elements{\r\n\t\t\t\t    display: block;\r\n\t\t\t\t}.tdi_17 > .wpb_wrapper > .tdc-elements{\r\n\t\t\t\t    width: 100%;\r\n\t\t\t\t}.tdi_17 > .wpb_wrapper > .vc_row_inner{\r\n\t\t\t\t    width: auto;\r\n\t\t\t\t}.tdi_17 > .wpb_wrapper{\r\n\t\t\t\t    width: auto;\r\n\t\t\t\t    height: auto;\r\n\t\t\t\t}\n<\/style><div class=\"wpb_wrapper\" ><div class=\"wpb_wrapper td_block_empty_space td_block_wrap vc_empty_space tdi_19 \"  style=\"height: 32px\"><\/div><\/div><\/div><\/div><\/div><div id=\"tdi_20\" class=\"tdc-row stretch_row\"><div class=\"vc_row tdi_21  wpb_row td-pb-row\" >\n<style scoped>\n\/* custom css - generated by TagDiv Composer *\/\n\n\/* custom css - generated by TagDiv Composer *\/\n.tdi_21,\r\n                .tdi_21 .tdc-columns{\r\n                    min-height: 0;\r\n                }.tdi_21,\r\n\t\t\t\t.tdi_21 .tdc-columns{\r\n\t\t\t\t    display: block;\r\n\t\t\t\t}.tdi_21 .tdc-columns{\r\n\t\t\t\t    width: 100%;\r\n\t\t\t\t}.tdi_21:before,\r\n\t\t\t\t.tdi_21:after{\r\n\t\t\t\t    display: table;\r\n\t\t\t\t}\n<\/style><div class=\"vc_column tdi_23  wpb_column vc_column_container tdc-column td-pb-span12\">\n<style scoped>\n\/* custom css - generated by TagDiv Composer *\/\n\n\/* custom css - generated by TagDiv Composer *\/\n.tdi_23{\r\n                    vertical-align: baseline;\r\n                }.tdi_23 > .wpb_wrapper,\r\n\t\t\t\t.tdi_23 > .wpb_wrapper > .tdc-elements{\r\n\t\t\t\t    display: block;\r\n\t\t\t\t}.tdi_23 > .wpb_wrapper > .tdc-elements{\r\n\t\t\t\t    width: 100%;\r\n\t\t\t\t}.tdi_23 > .wpb_wrapper > .vc_row_inner{\r\n\t\t\t\t    width: auto;\r\n\t\t\t\t}.tdi_23 > .wpb_wrapper{\r\n\t\t\t\t    width: auto;\r\n\t\t\t\t    height: auto;\r\n\t\t\t\t}\n<\/style><div class=\"wpb_wrapper\" ><div class=\"td_block_wrap td_block_text_with_title tdi_24 tagdiv-type td-pb-border-top td_block_template_1\"  data-td-block-uid=\"tdi_24\" >\n<style>\n\/* custom css - generated by TagDiv Composer *\/\n.td_block_text_with_title{\r\n                  margin-bottom: 44px;\r\n                  -webkit-transform: translateZ(0);\r\n                  transform: translateZ(0);\r\n                }.td_block_text_with_title p:last-child{\r\n                  margin-bottom: 0;\r\n                }\n<\/style><div class=\"td-block-title-wrap\"><\/div><div class=\"td_mod_wrap td-fix-index\"><h2 style=\"text-align: center;\">The table below contains those trials currently enrolling Duchenne patients and involving active therapies, as of the date indicated.<\/h2>\n<\/div><\/div><\/div><\/div><\/div><\/div><div id=\"tdi_25\" class=\"tdc-row stretch_row_1600 td-stretch-content\"><div class=\"vc_row tdi_26  wpb_row td-pb-row\" >\n<style scoped>\n\/* custom css - generated by TagDiv Composer *\/\n\n\/* custom css - generated by TagDiv Composer *\/\n.tdi_26,\r\n                .tdi_26 .tdc-columns{\r\n                    min-height: 0;\r\n                }.tdi_26,\r\n\t\t\t\t.tdi_26 .tdc-columns{\r\n\t\t\t\t    display: block;\r\n\t\t\t\t}.tdi_26 .tdc-columns{\r\n\t\t\t\t    width: 100%;\r\n\t\t\t\t}.tdi_26:before,\r\n\t\t\t\t.tdi_26:after{\r\n\t\t\t\t    display: table;\r\n\t\t\t\t}\n<\/style><div class=\"vc_column tdi_28  wpb_column vc_column_container tdc-column td-pb-span12\">\n<style scoped>\n\/* custom css - generated by TagDiv Composer *\/\n\n\/* custom css - generated by TagDiv Composer *\/\n.tdi_28{\r\n                    vertical-align: baseline;\r\n                }.tdi_28 > .wpb_wrapper,\r\n\t\t\t\t.tdi_28 > .wpb_wrapper > .tdc-elements{\r\n\t\t\t\t    display: block;\r\n\t\t\t\t}.tdi_28 > .wpb_wrapper > .tdc-elements{\r\n\t\t\t\t    width: 100%;\r\n\t\t\t\t}.tdi_28 > .wpb_wrapper > .vc_row_inner{\r\n\t\t\t\t    width: auto;\r\n\t\t\t\t}.tdi_28 > .wpb_wrapper{\r\n\t\t\t\t    width: auto;\r\n\t\t\t\t    height: auto;\r\n\t\t\t\t}\n<\/style><div class=\"wpb_wrapper\" ><div class=\"td_block_wrap td_block_text_with_title tdi_29 tagdiv-type td-pb-border-top td_block_template_1\"  data-td-block-uid=\"tdi_29\" ><div class=\"td-block-title-wrap\"><\/div><div class=\"td_mod_wrap td-fix-index\"><p>Last updated: July 1, 2026<\/p>\n<\/div><\/div><div class=\"td_block_wrap td_block_text_with_title tdi_30 tagdiv-type td-pb-border-top td_block_template_1\"  data-td-block-uid=\"tdi_30\" ><div class=\"td-block-title-wrap\"><\/div><div class=\"td_mod_wrap td-fix-index\"><p>For a comprehensive overview, please visit ClinicalTrials.gov and EUclinicaltrials.eu. If you need assistance in understanding clinical trials, we recommend reading our blog post which provides detailed insights to help you navigate and interpret the available information effectively. &#8211; &#8216;<a href=\"https:\/\/dmdwarrior.com\/how-to-participate-in-clinical-trials-for-duchenne\/\" target=\"_blank\" rel=\"noopener\">How to Participate in Clinical Trials for Duchenne (DMD)?<\/a>&#8216; &#8211;<\/p>\n<\/div><\/div><div class=\"td_block_wrap td_block_text_with_title tdi_31 tagdiv-type td-pb-border-top td_block_template_1\"  data-td-block-uid=\"tdi_31\" ><div class=\"td-block-title-wrap\"><\/div><div class=\"td_mod_wrap td-fix-index\"><div id=\"footable_parent_4606\"\n         class=\" footable_parent ninja_table_wrapper loading_ninja_table wp_table_data_press_parent bootstrap3 colored_table\">\n                        <div\n                class=\"table_description footable_description\"><h1>Gene Therapy<\/h1><\/div>\n                    <table data-ninja_table_instance=\"ninja_table_instance_0\" data-footable_id=\"4606\" data-filter-delay=\"1000\" aria-label=\"Gene Therapy\"            id=\"footable_4606\"\n           data-unique_identifier=\"ninja_table_unique_id_2714958380_4606\"\n           class=\" foo-table ninja_footable foo_table_4606 ninja_table_unique_id_2714958380_4606 table  ninja_search_right nt_type_legacy_table table-striped table-bordered vertical_centered ninja_custom_color inverted footable-paging-right ninja_table_search_disabled ninja_table_pro\">\n                <colgroup>\n                            <col class=\"ninja_column_0 \">\n                            <col class=\"ninja_column_1 \">\n                            <col class=\"ninja_column_2 \">\n                            <col class=\"ninja_column_3 \">\n                            <col class=\"ninja_column_4 \">\n                            <col class=\"ninja_column_5 \">\n                    <\/colgroup>\n        <thead>\n<tr class=\"footable-header\">\n                                                                                                        <th scope=\"col\"  class=\"ninja_column_0 ninja_clmn_nm_company \">Company<\/th><th scope=\"col\"  class=\"ninja_column_1 ninja_clmn_nm_drug \">Drug<\/th><th scope=\"col\"  class=\"ninja_column_2 ninja_clmn_nm_phase \">Phase<\/th><th scope=\"col\"  class=\"ninja_column_3 ninja_clmn_nm_indicationampinclusioncriteria \">Indication & Inclusion Criteria<\/th><th scope=\"col\"  class=\"ninja_column_4 ninja_clmn_nm_locations \">Locations<\/th><th scope=\"col\"  class=\"ninja_column_5 ninja_clmn_nm_clinicaltrial \">Clinical Trial<\/th><\/tr>\n<\/thead>\n<tbody>\n\n        <tr data-row_id=\"0\" class=\"ninja_table_row_0 nt_row_id_0\">\n            <td><a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.google.com\/url?q=https:\/\/www.sarepta.com\/products-pipeline\/clinical-trials&amp;sa=D&amp;source=editors&amp;ust=1783224176727373&amp;usg=AOvVaw2wwInTreWgmqsnJLXtCqd8\">Sarepta Therapeutics<\/a><\/td><td>SRP-9001-303<br \/>(Delandistrogene<br \/>Moxeparvovec)<\/td><td>Phase 3<\/td><td>Duchenne Muscular Dystrophy<br \/>Non-ambulatory or<br \/>Ambulatory 8 Years to 18 Years<\/td><td>USA (AR, CA, FL, IL, IA, MD, MA, MO, NY, NC, OH, PA, VA)<br \/>AUS, BEL, DEU, HKG, ISR, ITA, JPN, KOR, ESP, SWE, TWN, GBR<\/td><td><a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.google.com\/url?q=https:\/\/www.clinicaltrials.gov\/study\/NCT05881408?term%3Denvision&amp;sa=D&amp;source=editors&amp;ust=1783224176727690&amp;usg=AOvVaw1LmgR99i7hDrRSRCXZFky3\">NCT05881408<br \/>(ENVISION)<\/a><\/td>        <\/tr>\n            <tr data-row_id=\"1\" class=\"ninja_table_row_1 nt_row_id_1\">\n            <td><a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.google.com\/url?q=https:\/\/www.sarepta.com\/products-pipeline\/clinical-trials&amp;sa=D&amp;source=editors&amp;ust=1783224176727801&amp;usg=AOvVaw3g8XO8s6qifdokt65BAtI8\">Sarepta Therapeutics<\/a><\/td><td>SRP-9001-401<br \/>(Delandistrogene<br \/>Moxeparvovec)<\/td><td>Phase 4<\/td><td>An Observational Study Comparing Delandistrogene Moxeparvovec With Standard of Care in Participants With Duchenne Muscular Dystrophy<\/td><td>USA (AK, CO, DC, FL, IN, KS, MI, PA, TN, TX, VA)<\/td><td><a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.google.com\/url?q=https:\/\/clinicaltrials.gov\/study\/NCT06270719&amp;sa=D&amp;source=editors&amp;ust=1783224176727957&amp;usg=AOvVaw0XTOFy6Tx_ouhwWPAKtvUQ\">NCT06270719<br \/>(ENDURE)<\/a><\/td>        <\/tr>\n            <tr data-row_id=\"2\" class=\"ninja_table_row_2 nt_row_id_2\">\n            <td><a target=\"_blank\" rel=\"noreferrer\" href=\"https:\/\/www.google.com\/url?q=https:\/\/dmdwarrior.com\/elevidys-gene-therapy-for-non-ambulant-children-with-dmd-fda-oks-endeavor-cohort-8-immunosuppression-study\/&amp;sa=D&amp;source=editors&amp;ust=1783224176728071&amp;usg=AOvVaw1anfr4RkTdE-J3IuTc9bIY\">Sarepta Therapeutics<\/a><\/td><td>SRP-9001-103<br \/>(Delandistrogene<br \/>Moxeparvovec)<\/td><td>Phase 1<\/td><td>An Interventional Study<br \/>Ambulatory and non-ambulatory Participants<br \/>2 Years to 18 Years<\/td><td>USA (CA, MO, OH, VA)<\/td><td><span style=\"text-decoration:underline;color:#1155cc\"><a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.google.com\/url?q=https:\/\/clinicaltrials.gov\/study\/NCT04626674&amp;sa=D&amp;source=editors&amp;ust=1783224176728333&amp;usg=AOvVaw0SpuqnH3JP6QlVCUBiiB4c\">NCT04626674<\/a><\/span><br \/>(ENDEAVOR)<\/td>        <\/tr>\n            <tr data-row_id=\"3\" class=\"ninja_table_row_3 nt_row_id_3\">\n            <td>Sarepta Therapeutics<\/td><td>SRP-9001-104<br \/>(Delandistrogene<br \/>Moxeparvovec)<br \/><span style=\"text-decoration:underline;color:#1155cc\"><a target=\"_blank\" rel=\"noreferrer\" href=\"https:\/\/www.google.com\/url?q=https:\/\/dmdwarrior.com\/hansa-imlifidase-reduce-anti-aav-antibodies-and-allow-administration-of-gene-therapy\/&amp;sa=D&amp;source=editors&amp;ust=1783224176728549&amp;usg=AOvVaw07rCeMeMAIkowS3DOD0vtC\">Imlifidase<\/a><\/span><\/td><td>Phase 1<\/td><td>Ambulatory 4 Years to 9 Years (Child)<\/td><td>Spain<\/td><td>NCT06241950<\/td>        <\/tr>\n            <tr data-row_id=\"4\" class=\"ninja_table_row_4 nt_row_id_4\">\n            <td><a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.google.com\/url?q=https:\/\/www.sarepta.com\/products-pipeline\/clinical-trials&amp;sa=D&amp;source=editors&amp;ust=1783224176728839&amp;usg=AOvVaw2S5v7jzzwqjtyUMtNipbOk\">Sarepta Therapeutics<\/a><\/td><td>SRP-9001-105<br \/>(Delandistrogene<br \/>Moxeparvovec)<\/td><td>Phase 1<\/td><td>Duchenne Muscular Dystrophy<br \/>Patients with pre-existing AAV Abs<br \/>4 Years to 8 Years<\/td><td>USA (MO, OH)<\/td><td><a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.google.com\/url?q=https:\/\/clinicaltrials.gov\/study\/NCT06597656&amp;sa=D&amp;source=editors&amp;ust=1783224176729090&amp;usg=AOvVaw2mbIq5-yxeduXqZyhdR1D-\">NCT06597656<br \/>(HORIZON)<\/a><\/td>        <\/tr>\n            <tr data-row_id=\"5\" class=\"ninja_table_row_5 nt_row_id_5\">\n            <td>Sarepta Therapeutics<\/td><td>SRP-9001-305<br \/>(Delandistrogene<br \/>Moxeparvovec)<\/td><td>Phase 3<\/td><td>A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study (EXPEDITION)<\/td><td>USA, BEL, GER, HONG KONG, IT, JP, SP, TH, UK<\/td><td><a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.google.com\/url?q=https:\/\/clinicaltrials.gov\/study\/NCT05967351&amp;sa=D&amp;source=editors&amp;ust=1783224176729473&amp;usg=AOvVaw1edJj-BlKjpOgeiy0KtktC\">NCT05967351<\/a><\/td>        <\/tr>\n            <tr data-row_id=\"6\" class=\"ninja_table_row_6 nt_row_id_6\">\n            <td><a target=\"_blank\" rel=\"noreferrer\" href=\"https:\/\/www.google.com\/url?q=https:\/\/dmdwarrior.com\/elevidys-phase-4-enhance-clinical-trial-nct07542314\/&amp;sa=D&amp;source=editors&amp;ust=1783224176729605&amp;usg=AOvVaw3yzoBuQGzAu_5zygJmOWT8\">Sarepta Therapeutics<\/a><\/td><td>SRP-9001-402<br \/>(Delandistrogene<br \/>Moxeparvovec)<\/td><td>Phase 4<\/td><td>Phase 4 Study to Evaluate the Safety and Effectiveness of ELEVIDYS in Patients With Duchenne Muscular Dystrophy Treated in a Post-Marketing Setting<\/td><td>NA<\/td><td><span style=\"text-decoration:underline;color:#0563c1\"><a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.google.com\/url?q=https:\/\/clinicaltrials.gov\/study\/NCT07542314&amp;sa=D&amp;source=editors&amp;ust=1783224176729894&amp;usg=AOvVaw0fqcfEMtJ79eMR0UcmMpaY\">NCT07542314<br \/><\/a><\/span><span style=\"color:#1f1f1f\">ENHANCE<\/span><\/td>        <\/tr>\n            <tr data-row_id=\"7\" class=\"ninja_table_row_7 nt_row_id_7\">\n            <td>Roche<\/td><td>Delandistrogene<br \/>Moxeparvovec<\/td><td>Phase 2<\/td><td>Duchenne Muscular Dystrophy<br \/>Up to 3 Years<br \/>Mutation between Exons 18 and 79<\/td><td>BEL, DEU, FRA, ITA, ESP, GBR<\/td><td><a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.google.com\/url?q=https:\/\/clinicaltrials.gov\/study\/NCT06128564&amp;sa=D&amp;source=editors&amp;ust=1783224176730240&amp;usg=AOvVaw0IHNvzy4fncEE_7Zj4hmET\">NCT06128564<br \/>(ENVOL)<\/a><\/td>        <\/tr>\n            <tr data-row_id=\"8\" class=\"ninja_table_row_8 nt_row_id_8\">\n            <td><a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.google.com\/url?q=https:\/\/www.genethon.com\/our-pipeline\/duchenne-muscular-dystrophy\/&amp;sa=D&amp;source=editors&amp;ust=1783224176730353&amp;usg=AOvVaw1jcwSqlIoBLU5zKlc9oDDU\">Genethon<\/a><\/td><td>GNT 0004<\/td><td>Pivotal Phase<\/td><td>5 patients aged 6 and 10 have been treated with GNT0004, 4 in France and 1<br \/>in the UK.<\/td><td>FR, UK<\/td><td><a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.google.com\/url?q=https:\/\/www.genethon.com\/genethon-presents-positive-initial-results-from-a-phase-1-2-3-trial-of-its-gene-therapy-gnt0004-for-duchenne-muscular-dystrophy-at-asgct-breakthroughs-in-muscular-dystrophy-in-chicago\/&amp;sa=D&amp;source=editors&amp;ust=1783224176730631&amp;usg=AOvVaw3XH6I9yOFDSsqr7azlnnvJ\">GNT-016-MDYF<\/a><\/td>        <\/tr>\n            <tr data-row_id=\"9\" class=\"ninja_table_row_9 nt_row_id_9\">\n            <td><a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.google.com\/url?q=https:\/\/www.regenxbio.com\/rgx-202\/&amp;sa=D&amp;source=editors&amp;ust=1783224176730778&amp;usg=AOvVaw1w9vmD5pzEZjDAtSAMhgFc\">RegenxBio<\/a><\/td><td>RGX-202<\/td><td>Phase 1 &amp; 2 &amp; 3<\/td><td>Duchenne Muscular Dystrophy<br \/>1 Year and older<br \/>Ambulatory<br \/>Mutation in Exons 18 and above<\/td><td>USA (AR, CA, CO, IL, TX, VA)<\/td><td><span style=\"text-decoration:underline;color:#0563c1\"><a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.google.com\/url?q=https:\/\/clinicaltrials.gov\/study\/NCT05693142&amp;sa=D&amp;source=editors&amp;ust=1783224176730958&amp;usg=AOvVaw2KrghnZX9BrCjkOnchc1IZ\">NCT05693142<br \/><\/a><\/span><span style=\"text-decoration:underline;color:#1155cc\"><a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.google.com\/url?q=https:\/\/clinicaltrials.gov\/study\/NCT05683379&amp;sa=D&amp;source=editors&amp;ust=1783224176730986&amp;usg=AOvVaw2SVRSkNm6D90T3WZqtUyiE\">NCT05683379<\/a><\/span><\/td>        <\/tr>\n            <tr data-row_id=\"10\" class=\"ninja_table_row_10 nt_row_id_10\">\n            <td><a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.google.com\/url?q=https:\/\/www.solidbio.com\/our-science\/pipeline-programs\/pipeline\/&amp;sa=D&amp;source=editors&amp;ust=1783224176731053&amp;usg=AOvVaw17Z_86vtjcJTz7h5DpjHDs\">Solid Biosciences<\/a><\/td><td>SGT-001<\/td><td>Phase 1 &amp; 2<\/td><td>Duchenne Muscular Dystrophy<br \/>4 Years to 17 Years (Child)<\/td><td>USA (CA, FL)<\/td><td><a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.google.com\/url?q=https:\/\/www.clinicaltrials.gov\/study\/NCT03368742&amp;sa=D&amp;source=editors&amp;ust=1783224176731189&amp;usg=AOvVaw3dvgOLTHbXX9QUWm3flqS8\">NCT03368742<\/a><\/td>        <\/tr>\n            <tr data-row_id=\"11\" class=\"ninja_table_row_11 nt_row_id_11\">\n            <td><a target=\"_blank\" rel=\"noreferrer\" href=\"https:\/\/www.google.com\/url?q=https:\/\/dmdwarrior.com\/tr\/solid-biosciences-sgt-003-gene-therapy-phase-3-clinical-trial-nct07160634\/&amp;sa=D&amp;source=editors&amp;ust=1783224176731246&amp;usg=AOvVaw0AA6U6TYSDv45WEHtDPrBZ\">Solid Biosciences<\/a><\/td><td>SGT-003<br \/>IMPACT DUCHENNE<\/td><td>Phase 3<\/td><td>7 Years to 11 Years (Child)<br \/>Exclusion Criteria: Established clinical diagnosis of DMD that is associated with any deletion mutation in exons 1 to 11 or exons 42 to 45, inclusive, of the DMD gene as documented by a genetic report.<br \/><\/td><td>Australia, Canada<\/td><td><a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.google.com\/url?q=https:\/\/clinicaltrials.gov\/study\/NCT07160634&amp;sa=D&amp;source=editors&amp;ust=1783224176731378&amp;usg=AOvVaw2yvZ67ExxWK61h7w4hMEpe\">NCT07160634<\/a><\/td>        <\/tr>\n            <tr data-row_id=\"12\" class=\"ninja_table_row_12 nt_row_id_12\">\n            <td><a target=\"_blank\" rel=\"noreferrer\" href=\"https:\/\/www.google.com\/url?q=https:\/\/dmdwarrior.com\/tr\/solid-biosciences-sgt-003-gene-therapy-phase-3-clinical-trial-nct07160634\/&amp;sa=D&amp;source=editors&amp;ust=1783224176731479&amp;usg=AOvVaw3LY5OAzCZ2zQtuLinDYAtA\">Solid Biosciences<\/a><\/td><td>SGT-003<br \/><span style=\"text-decoration:underline;color:#1155cc\"><a target=\"_blank\" rel=\"noreferrer\" href=\"https:\/\/www.google.com\/url?q=https:\/\/dmdwarrior.com\/inspire-duchenne-sgt-003-clinical-trial-update\/&amp;sa=D&amp;source=editors&amp;ust=1783224176731526&amp;usg=AOvVaw1xcg-dwjGX7ItF9LCC8wu-\">INSPIRE DUCHENNE<\/a><\/span><\/td><td>Phase 3<\/td><td>0 Years to 17 Years (Child)<br \/>Exclusion Criteria: Established clinical diagnosis of DMD that is associated with any deletion mutation in exons 1 to 11 or exons 42 to 45, inclusive, of the DMD gene as documented by a genetic report.<br \/><\/td><td>USA, Canada, Italy, United Kingdom<\/td><td><a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.google.com\/url?q=https:\/\/clinicaltrials.gov\/study\/NCT06138639&amp;sa=D&amp;source=editors&amp;ust=1783224176731638&amp;usg=AOvVaw0PVNBZenbvp5Uqut8K95lv\">NCT06138639<\/a><\/td>        <\/tr>\n            <tr data-row_id=\"13\" class=\"ninja_table_row_13 nt_row_id_13\">\n            <td><a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.google.com\/url?q=https:\/\/www.beliefbiomed.com\/en\/pipeline.html&amp;sa=D&amp;source=editors&amp;ust=1783224176731694&amp;usg=AOvVaw3-GGKIcth1ErdvQ4sj2J2M\">Belief BioMed<\/a><\/td><td>BBM-D101<\/td><td>Phase 1<\/td><td>Duchenne Muscular Dystrophy<br \/>4 Years to 8 Years<\/td><td>Chine (Shanghai)<\/td><td><a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.google.com\/url?q=https:\/\/clinicaltrials.gov\/study\/NCT06641895&amp;sa=D&amp;source=editors&amp;ust=1783224176731809&amp;usg=AOvVaw2RpEUvFoM9SlJrK70i1ZuK\">NCT06641895<\/a><\/td>        <\/tr>\n            <tr data-row_id=\"14\" class=\"ninja_table_row_14 nt_row_id_14\">\n            <td><a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.google.com\/url?q=https:\/\/insmed.com\/science\/pipeline\/&amp;sa=D&amp;source=editors&amp;ust=1783224176731866&amp;usg=AOvVaw0YjOPb33fL3tvqlIKiFc6J\">Insmed<\/a><\/td><td>INS1201<\/td><td>Phase 1<\/td><td>Duchenne Muscular Dystrophy<br \/>2 Years to 4 Years<br \/>Ambulatory<br \/>Mutation between Exons 18 and 58<\/td><td>USA (GA)<\/td><td><a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.google.com\/url?q=https:\/\/clinicaltrials.gov\/study\/NCT06817382&amp;sa=D&amp;source=editors&amp;ust=1783224176731990&amp;usg=AOvVaw1rybuOmwG2eRTkEqN9g5MO\">NCT06817382<\/a><\/td>        <\/tr>\n            <tr data-row_id=\"15\" class=\"ninja_table_row_15 nt_row_id_15\">\n            <td>Shanghai Siponuoyin Biotechnology<\/td><td><a target=\"_blank\" rel=\"noreferrer\" href=\"https:\/\/www.google.com\/url?q=https:\/\/dmdwarrior.com\/spot-mrna03-gene-therapy-early-phase-1-clinical-trial-nct07188012\/&amp;sa=D&amp;source=editors&amp;ust=1783224176732068&amp;usg=AOvVaw1mewdJyZwpL8_Tx_hOKlst\">SPOT-mRNA03<\/a><\/td><td>Early Phase 1<\/td><td>2 Years to 6 Years (Ambulant Males)<\/td><td>China<\/td><td><a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.google.com\/url?q=https:\/\/clinicaltrials.gov\/study\/NCT07188012&amp;sa=D&amp;source=editors&amp;ust=1783224176732172&amp;usg=AOvVaw1Tq9l0KDBdHDC0lwpawVxO\">NCT07188012<\/a><\/td>        <\/tr>\n            <tr data-row_id=\"16\" class=\"ninja_table_row_16 nt_row_id_16\">\n            <td><a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.google.com\/url?q=https:\/\/ultragenyx-pipeline.com\/&amp;sa=D&amp;source=editors&amp;ust=1783224176732223&amp;usg=AOvVaw2MXWmq6QfDQYdelOw9nOtC\">Ultragenyx<\/a><\/td><td>UX810<\/td><td>Early Phase 1<\/td><td>NA<\/td><td>NA<\/td><td>NA<\/td>        <\/tr>\n            <tr data-row_id=\"17\" class=\"ninja_table_row_17 nt_row_id_17\">\n            <td><a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.google.com\/url?q=https:\/\/www.generium.ru\/en\/pipeline\/&amp;sa=D&amp;source=editors&amp;ust=1783224176732375&amp;usg=AOvVaw3iA0YpuNEwhZciLTbbCjLh\">Generium<\/a><\/td><td><a target=\"_blank\" rel=\"noreferrer\" href=\"https:\/\/www.google.com\/url?q=https:\/\/dmdwarrior.com\/gnr-097-duchenne-gene-therapy-phase-1-2-study-started-by-generium\/&amp;sa=D&amp;source=editors&amp;ust=1783224176732427&amp;usg=AOvVaw1v-z5cr00rX-c9vZj5xGoJ\">GNR-097<\/a><\/td><td>Phase 1\/2<\/td><td>4 Years to 9 Years (Child)<br \/>Mutations in exons 8 and\/or 9 of the DMD gene; for patients planned for inclusion in Cohort A, additionally: mutations in exons 1-17 and\/or 59-71 of the DMD gene.<\/td><td>Russia, Belarus<\/td><td><a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.google.com\/url?q=https:\/\/clinicaltrials.gov\/study\/NCT07673809&amp;sa=D&amp;source=editors&amp;ust=1783224176732524&amp;usg=AOvVaw1Qym4VhKolZtRMXv4DjDro\">NCT07673809<\/a><\/td>        <\/tr>\n            <tr data-row_id=\"18\" class=\"ninja_table_row_18 nt_row_id_18\">\n            <td>Kinea Bio<\/td><td>KNA-123<br \/>Midi-Dystrophin Gene Therapy<\/td><td>Pre-Clinical<\/td><td>NA<\/td><td>NA<\/td><td>NA<\/td>        <\/tr>\n    <\/tbody><!--ninja_tobody_rendering_done-->\n<!--ninja_cached_data-->    <\/table>\n    \n    \n    \n<\/div>\n\n<\/div><\/div><div class=\"td_block_wrap td_block_text_with_title tdi_32 tagdiv-type td-pb-border-top td_block_template_1\"  data-td-block-uid=\"tdi_32\" ><div class=\"td-block-title-wrap\"><\/div><div class=\"td_mod_wrap td-fix-index\"><div id=\"footable_parent_4640\"\n         class=\" footable_parent ninja_table_wrapper loading_ninja_table wp_table_data_press_parent bootstrap3 colored_table\">\n                        <div\n                class=\"table_description footable_description\"><h1>Exon Skipping<\/h1><\/div>\n                    <table data-ninja_table_instance=\"ninja_table_instance_1\" data-footable_id=\"4640\" data-filter-delay=\"1000\" aria-label=\"Exon Skipping\"            id=\"footable_4640\"\n           data-unique_identifier=\"ninja_table_unique_id_1941536648_4640\"\n           class=\" foo-table ninja_footable foo_table_4640 ninja_table_unique_id_1941536648_4640 table  ninja_search_right nt_type_legacy_table table-striped table-bordered vertical_centered ninja_custom_color inverted footable-paging-right ninja_table_search_disabled ninja_table_pro\">\n                <colgroup>\n                            <col class=\"ninja_column_0 \">\n                            <col class=\"ninja_column_1 \">\n                            <col class=\"ninja_column_2 \">\n                            <col class=\"ninja_column_3 \">\n                            <col class=\"ninja_column_4 \">\n                            <col class=\"ninja_column_5 \">\n                    <\/colgroup>\n        <thead>\n<tr class=\"footable-header\">\n                                                                                                        <th scope=\"col\"  class=\"ninja_column_0 ninja_clmn_nm_company \">Company<\/th><th scope=\"col\"  class=\"ninja_column_1 ninja_clmn_nm_drug \">Drug<\/th><th scope=\"col\"  class=\"ninja_column_2 ninja_clmn_nm_phase \">Phase<\/th><th scope=\"col\"  class=\"ninja_column_3 ninja_clmn_nm_indicationampinclusioncriteria \">Indication & Inclusion Criteria<\/th><th scope=\"col\"  class=\"ninja_column_4 ninja_clmn_nm_locations \">Locations<\/th><th scope=\"col\"  class=\"ninja_column_5 ninja_clmn_nm_clinicaltrial \">Clinical Trial<\/th><\/tr>\n<\/thead>\n<tbody>\n\n        <tr data-row_id=\"0\" class=\"ninja_table_row_0 nt_row_id_0\">\n            <td>NS Pharma<\/td><td>NS-089\/NCNP-02<br \/>(Exon 44)<\/td><td>Phase 2<\/td><td>Duchenne Muscular Dystrophy<br \/>4 Years to 14 years<br \/>Ambulatory<br \/>Amenable to exon 44 skipping<\/td><td>USA (CO, GA, IL, KS, OH, OR, PA, TX, VA)<br \/>Canada, Japan, South Korea, Turkiye<\/td><td><a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.google.com\/url?q=https:\/\/clinicaltrials.gov\/study\/NCT05996003&amp;sa=D&amp;source=editors&amp;ust=1783226708979670&amp;usg=AOvVaw3sOFt2z7qCE3O0DHviSAnj\">NCT05996003<\/a><\/td>        <\/tr>\n            <tr data-row_id=\"1\" class=\"ninja_table_row_1 nt_row_id_1\">\n            <td>NS Pharma<\/td><td>        <br \/>NS\u2010050\/NCNP\u201003<br \/>(Exon 50)<\/td><td>Phase 1 &amp; 2<\/td><td>Duchenne Muscular Dystrophy<br \/>4 Years to 14 years<br \/>Ambulatory<br \/>Amenable to exon 50 skipping<\/td><td>USA (CO, GA, IL, KS, OH, OR, PA, TX, VA)<br \/>Canada, Japan, South Korea, Turkiye<\/td><td><a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.google.com\/url?q=https:\/\/clinicaltrials.gov\/study\/NCT06053814&amp;sa=D&amp;source=editors&amp;ust=1783226708980076&amp;usg=AOvVaw2XdXBjDi2cUbQ4pYd5SKCN\">NCT06053814<\/a><\/td>        <\/tr>\n            <tr data-row_id=\"2\" class=\"ninja_table_row_2 nt_row_id_2\">\n            <td>NS Pharma<\/td><td>NS-051\/NCNP-04<br \/>(Exon 51)<\/td><td>Pre-Clinical<\/td><td>NA<\/td><td>NA<\/td><td>NA<\/td>        <\/tr>\n            <tr data-row_id=\"3\" class=\"ninja_table_row_3 nt_row_id_3\">\n            <td><div class=\"softmerge-inner\" style=\"width:198px;left:-11px\">Nationwide Children's Hospital<\/div><\/td><td>AAV9 U7snRNA<br \/>(Exon 2 Duplications)<\/td><td>Phase 1 &amp; 2<\/td><td>6 Months to 13 Years (Child)<br \/>Confirmed duplication of exon 2 in the DMD gene<\/td><td>USA (OH)<\/td><td><a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.google.com\/url?q=https:\/\/clinicaltrials.gov\/study\/NCT04240314&amp;sa=D&amp;source=editors&amp;ust=1783226708980482&amp;usg=AOvVaw0LP0riKYVb5fXGPJ1NDIL3\">NCT04240314<\/a><\/td>        <\/tr>\n            <tr data-row_id=\"4\" class=\"ninja_table_row_4 nt_row_id_4\">\n            <td>Wave Life Sciences<\/td><td>WVE-N531<br \/>(Exon 53)<\/td><td>Phase 2<\/td><td>4 Years to 18 Years (Child,  Adult)<br \/>Amenable to exon 53 skipping<\/td><td>Jordan, United Kingdom<\/td><td><span style=\"text-decoration:underline;color:#0563c1\"><a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.google.com\/url?q=https:\/\/clinicaltrials.gov\/study\/NCT04906460&amp;sa=D&amp;source=editors&amp;ust=1783226708980738&amp;usg=AOvVaw292d6Col4DPj1i8Gdu-XDt\">NCT04906460<br \/><\/a><\/span><span style=\"text-decoration:underline;color:#1155cc\"><a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.google.com\/url?q=https:\/\/clinicaltrials.gov\/study\/NCT07209332&amp;sa=D&amp;source=editors&amp;ust=1783226708980786&amp;usg=AOvVaw08sMdtZxH9SoFKrhALh3YH\">NCT07209332<\/a><\/span><\/td>        <\/tr>\n            <tr data-row_id=\"5\" class=\"ninja_table_row_5 nt_row_id_5\">\n            <td>Avidity Biosciences<\/td><td>AOC 1044<br \/>(Exon 44)<\/td><td>Phase 2<\/td><td>7 Years to 27 Years (Child,  Adult)<br \/>Amenable to exon 44 skipping<\/td><td>USA<\/td><td><a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.google.com\/url?q=https:\/\/clinicaltrials.gov\/study\/NCT06244082&amp;sa=D&amp;source=editors&amp;ust=1783226708981010&amp;usg=AOvVaw3X932Y-AeRBEA6pp_BnP0G\">NCT06244082<\/a><\/td>        <\/tr>\n            <tr data-row_id=\"6\" class=\"ninja_table_row_6 nt_row_id_6\">\n            <td><a target=\"_blank\" rel=\"noreferrer\" href=\"https:\/\/www.google.com\/url?q=https:\/\/dmdwarrior.com\/avidity-biosciences-aoc-1044-safari44-phase-3-dmd-trial-nct07587242\/&amp;sa=D&amp;source=editors&amp;ust=1783226708981101&amp;usg=AOvVaw1sQHTqOWhH-nNaSfiV7Q2-\">Avidity Biosciences<\/a><\/td><td>AOC 1044<br \/>(Exon 44)<\/td><td>Phase 3<\/td><td>7 Years to 16 Years (Child)<br \/>Amenable to exon 44 skipping<\/td><td>NA<\/td><td><span style=\"text-decoration:underline;color:#1155cc\"><a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.google.com\/url?q=https:\/\/clinicaltrials.gov\/study\/NCT07587242&amp;sa=D&amp;source=editors&amp;ust=1783226708981287&amp;usg=AOvVaw10kMI_D4o6fTQL3VP3fl8T\">NCT07587242<\/a><\/span><br \/>(SAFARI44)<\/td>        <\/tr>\n            <tr data-row_id=\"7\" class=\"ninja_table_row_7 nt_row_id_7\">\n            <td>Avidity Biosciences<\/td><td>AOC 1045<br \/>(Exon 45)<\/td><td>Pre-Clinical<\/td><td>NA<\/td><td>NA<\/td><td>NA<\/td>        <\/tr>\n            <tr data-row_id=\"8\" class=\"ninja_table_row_8 nt_row_id_8\">\n            <td>Dyne Therapeutics<\/td><td>DYNE-251<br \/>(Exon 51)<\/td><td>Phase 1 &amp; 2<\/td><td>4 Years to 16 Years (Child)<br \/>Amenable to exon 51 skipping<\/td><td>USA, Australia, Belgium, Canada, Ireland, Italy, South Korea, Spain, United Kingdom<\/td><td><a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.google.com\/url?q=https:\/\/www.clinicaltrials.gov\/study\/NCT05524883&amp;sa=D&amp;source=editors&amp;ust=1783226708981696&amp;usg=AOvVaw3A_OzuV8pt2hO8D-RpIKqj\">NCT05524883<\/a><\/td>        <\/tr>\n            <tr data-row_id=\"9\" class=\"ninja_table_row_9 nt_row_id_9\">\n            <td>Dyne Therapeutics<\/td><td>Exon 44, 45, 53<\/td><td>Pre-Clinical<\/td><td>NA<\/td><td>NA<\/td><td>NA<\/td>        <\/tr>\n            <tr data-row_id=\"10\" class=\"ninja_table_row_10 nt_row_id_10\">\n            <td>PepGen<\/td><td>PGN-EDO51<br \/>(Exon 51)<\/td><td>Phase 2<\/td><td>6 Years to 16 Years (Child)<br \/>Amenable to exon 51 skipping<\/td><td>Canada<\/td><td><a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.google.com\/url?q=https:\/\/clinicaltrials.gov\/study\/NCT06079736&amp;sa=D&amp;source=editors&amp;ust=1783226708982114&amp;usg=AOvVaw163WxBdk-LgNqC7LUT1MYr\">NCT06079736<\/a><\/td>        <\/tr>\n            <tr data-row_id=\"11\" class=\"ninja_table_row_11 nt_row_id_11\">\n            <td>Entrada Therapeutics<\/td><td>ENTR-601-44<br \/>(Exon 44)<\/td><td>Phase 1 &amp; 2<\/td><td>4 Years to 20 Years (Child,  Adult)<br \/>Amenable to exon 44 skipping<\/td><td>Belgium, Italy, Spain, United Kingdom<\/td><td><a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.google.com\/url?q=https:\/\/clinicaltrials.gov\/study\/NCT07037862&amp;sa=D&amp;source=editors&amp;ust=1783226708982340&amp;usg=AOvVaw3hBemOTUEOr3wZb2QzDNhW\">NCT07037862<\/a><\/td>        <\/tr>\n            <tr data-row_id=\"12\" class=\"ninja_table_row_12 nt_row_id_12\">\n            <td>Entrada Therapeutics<\/td><td>ENTR-601-45<br \/>(Exon 45)<\/td><td>Phase 1 &amp; 2<\/td><td>4 Years to 20 Years (Child,  Adult)<br \/>Amenable to exon 45 skipping<\/td><td>Belgium, Italy, Netherlands, Spain, United Kingdom<\/td><td><a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.google.com\/url?q=https:\/\/clinicaltrials.gov\/study\/NCT07038824&amp;sa=D&amp;source=editors&amp;ust=1783226708982563&amp;usg=AOvVaw0GuXqm_dMyNnZMI7s5Vde0\">NCT07038824<\/a><\/td>        <\/tr>\n            <tr data-row_id=\"13\" class=\"ninja_table_row_13 nt_row_id_13\">\n            <td>Entrada Therapeutics<\/td><td>ENTR-601-50<br \/>(Exon 50)<\/td><td>Pre-Clinical<\/td><td>NA<\/td><td>NA<\/td><td>NA<\/td>        <\/tr>\n            <tr data-row_id=\"14\" class=\"ninja_table_row_14 nt_row_id_14\">\n            <td>Entrada Therapeutics<\/td><td>ENTR-601-51<br \/>(Exon 51)<\/td><td>Pre-Clinical<\/td><td>NA<\/td><td>NA<\/td><td>NA<\/td>        <\/tr>\n            <tr data-row_id=\"15\" class=\"ninja_table_row_15 nt_row_id_15\">\n            <td>BioMarin Pharmaceutical<\/td><td>BMN 351<br \/>(Exon 51)<\/td><td>Phase 1 &amp; 2<\/td><td>4 Years to 10 Years (Child)<br \/>Amenable to exon 51 skipping<\/td><td>Italy, Netherlands, Spain, Turkiye, United Kingdom<\/td><td><a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.google.com\/url?q=https:\/\/clinicaltrials.gov\/study\/NCT06280209&amp;sa=D&amp;source=editors&amp;ust=1783226708983115&amp;usg=AOvVaw1gRdY5eKSZyDmi-ge4YcbS\">NCT06280209<\/a><\/td>        <\/tr>\n            <tr data-row_id=\"16\" class=\"ninja_table_row_16 nt_row_id_16\">\n            <td><a target=\"_blank\" rel=\"noreferrer\" href=\"https:\/\/www.google.com\/url?q=https:\/\/dmdwarrior.com\/bmn-351-exon-51-skipping-therapy-phase-2-clinical-trial-nct07573631\/&amp;sa=D&amp;source=editors&amp;ust=1783226708983198&amp;usg=AOvVaw0aY3Dqhh4mm2Nuyre9SMlF\">BioMarin Pharmaceutical<\/a><\/td><td>BMN 351<br \/>(Exon 51)<\/td><td>Phase 2<\/td><td>4 Years and older (Child,  Adult,  Older Adult)<br \/>Participants must have completed 351-201<\/td><td>Italy, Netherlands, Spain, Turkiye, United Kingdom<\/td><td><a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.google.com\/url?q=https:\/\/clinicaltrials.gov\/study\/NCT07573631&amp;sa=D&amp;source=editors&amp;ust=1783226708983372&amp;usg=AOvVaw0CQsmJ2Nzx8-Ar1eLDvdxU\">NCT07573631<\/a><\/td>        <\/tr>\n            <tr data-row_id=\"17\" class=\"ninja_table_row_17 nt_row_id_17\">\n            <td>Jiao Tong University<\/td><td>LE051<br \/>(Exon 51)<\/td><td>Early Phase 1<\/td><td>4 Years to 8 Years (Child)<br \/>Amenable to exon 51 skipping<\/td><td>China<\/td><td><a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.google.com\/url?q=https:\/\/clinicaltrials.gov\/study\/NCT06900049&amp;sa=D&amp;source=editors&amp;ust=1783226708983592&amp;usg=AOvVaw0wwxxiDkfXgLgum-ofS_ya\">NCT06900049<\/a><\/td>        <\/tr>\n            <tr data-row_id=\"18\" class=\"ninja_table_row_18 nt_row_id_18\">\n            <td>Sqy Therapeutics<\/td><td>SQY51<br \/>(Exon 51)<\/td><td>Phase 1 &amp; 2<\/td><td>6 Years and older (Child,  Adult,  Older Adult)<br \/>Amenable to exon 51 skipping<\/td><td>France<\/td><td><a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.google.com\/url?q=https:\/\/clinicaltrials.gov\/study\/NCT05753462&amp;sa=D&amp;source=editors&amp;ust=1783226708983801&amp;usg=AOvVaw2zu652dmWSGGdaJ8GO7hJU\">NCT05753462<\/a><\/td>        <\/tr>\n    <\/tbody><!--ninja_tobody_rendering_done-->\n<!--ninja_cached_data-->    <\/table>\n    \n    \n    \n<\/div>\n\n<\/div><\/div><div class=\"td-block td-a-rec td-a-rec-id-custom-spot tdi_33 td_block_template_1\">\n<style>\n\/* custom css - generated by TagDiv Composer *\/\n.tdi_33.td-a-rec{\r\n\t\t\t\t\ttext-align: center;\r\n\t\t\t\t}.tdi_33.td-a-rec:not(.td-a-rec-no-translate){\r\n\t\t\t\t    transform: translateZ(0);\r\n\t\t\t\t}.tdi_33 .td-element-style{\r\n\t\t\t\t\tz-index: -1;\r\n\t\t\t\t}.tdi_33 .td_spot_img_all img,\r\n\t\t\t\t.tdi_33 .td_spot_img_tl img,\r\n\t\t\t\t.tdi_33 .td_spot_img_tp img,\r\n\t\t\t\t.tdi_33 .td_spot_img_mob img{\r\n\t\t\t\t    border-style: none;\r\n\t\t\t\t}\n<\/style><a target=\"_blank\" href=\"https:\/\/whatsapp.com\/channel\/0029VawlBUg5q08b6BIgRP0m\" rel=\"noopener\">\n<img decoding=\"async\" src=\"https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/08\/follow-us-on-whatsapp.jpg\" alt=\"DMD Warrior Whatsapp Channel\" title=\"\">\n<\/a><\/div><div class=\"td_block_wrap td_block_text_with_title tdi_34 tagdiv-type td-pb-border-top td_block_template_1\"  data-td-block-uid=\"tdi_34\" ><div class=\"td-block-title-wrap\"><\/div><div class=\"td_mod_wrap td-fix-index\"><div id=\"footable_parent_4643\"\n         class=\" footable_parent ninja_table_wrapper loading_ninja_table wp_table_data_press_parent bootstrap3 colored_table\">\n                        <div\n                class=\"table_description footable_description\"><h2>Reducing Inflammation<\/h2><\/div>\n                    <table data-ninja_table_instance=\"ninja_table_instance_2\" data-footable_id=\"4643\" data-filter-delay=\"1000\" aria-label=\"Reducing Inflammation\"            id=\"footable_4643\"\n           data-unique_identifier=\"ninja_table_unique_id_2872783085_4643\"\n           class=\" foo-table ninja_footable foo_table_4643 ninja_table_unique_id_2872783085_4643 table  ninja_search_right nt_type_legacy_table table-striped table-bordered vertical_centered ninja_custom_color inverted footable-paging-right ninja_table_search_disabled ninja_table_pro\">\n                <colgroup>\n                            <col class=\"ninja_column_0 \">\n                            <col class=\"ninja_column_1 \">\n                            <col class=\"ninja_column_2 \">\n                            <col class=\"ninja_column_3 \">\n                            <col class=\"ninja_column_4 \">\n                            <col class=\"ninja_column_5 \">\n                    <\/colgroup>\n        <thead>\n<tr class=\"footable-header\">\n                                                                                                        <th scope=\"col\"  class=\"ninja_column_0 ninja_clmn_nm_company \">Company<\/th><th scope=\"col\"  class=\"ninja_column_1 ninja_clmn_nm_drug \">Drug<\/th><th scope=\"col\"  class=\"ninja_column_2 ninja_clmn_nm_phase \">Phase<\/th><th scope=\"col\"  class=\"ninja_column_3 ninja_clmn_nm_indicationampinclusioncriteria \">Indication & Inclusion Criteria<\/th><th scope=\"col\"  class=\"ninja_column_4 ninja_clmn_nm_locations \">Locations<\/th><th scope=\"col\"  class=\"ninja_column_5 ninja_clmn_nm_clinicaltrial \">Clinical Trial<\/th><\/tr>\n<\/thead>\n<tbody>\n\n        <tr data-row_id=\"0\" class=\"ninja_table_row_0 nt_row_id_0\">\n            <td><div class=\"softmerge-inner\" style=\"width:198px;left:-11px\">Nationwide Children's Hospital<\/div><\/td><td>Prednisolone<\/td><td>Phase 4<\/td><td>1 Month to 30 Months (Child)<\/td><td>USA<\/td><td><a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.google.com\/url?q=https:\/\/clinicaltrials.gov\/study\/NCT05412394&amp;sa=D&amp;source=editors&amp;ust=1783226710787594&amp;usg=AOvVaw0ECnMjjYMH-XZWLQ-67Ind\">NCT05412394<\/a><\/td>        <\/tr>\n            <tr data-row_id=\"1\" class=\"ninja_table_row_1 nt_row_id_1\">\n            <td><div class=\"softmerge-inner\" style=\"width:221px;left:-34px\">Children's National Research Institute<\/div><\/td><td>Canakinumab<\/td><td>Phase 1 &amp; 2<\/td><td>2 Years and older (Child,  Adult,  Older Adult)<\/td><td>USA<\/td><td><a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.google.com\/url?q=https:\/\/clinicaltrials.gov\/study\/NCT03936894&amp;sa=D&amp;source=editors&amp;ust=1783226710787885&amp;usg=AOvVaw1tjW4bsIaleAguvz8vepO0\">NCT03936894<\/a><\/td>        <\/tr>\n            <tr data-row_id=\"2\" class=\"ninja_table_row_2 nt_row_id_2\">\n            <td>Gr\u00fcnenthal GmbH<\/td><td>GRT6019<\/td><td>Phase 1<\/td><td>18 Years to 55 Years (Adult)<\/td><td>USA<\/td><td><a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.google.com\/url?q=https:\/\/clinicaltrials.gov\/study\/NCT07317063&amp;sa=D&amp;source=editors&amp;ust=1783226710788178&amp;usg=AOvVaw3mok_jla-i-ip1i_cGUaA8\">NCT07317063<\/a><\/td>        <\/tr>\n    <\/tbody><!--ninja_tobody_rendering_done-->\n<!--ninja_cached_data-->    <\/table>\n    \n    \n    \n<\/div>\n\n<\/div><\/div><div class=\"td_block_wrap td_block_text_with_title tdi_35 tagdiv-type td-pb-border-top td_block_template_1\"  data-td-block-uid=\"tdi_35\" ><div class=\"td-block-title-wrap\"><\/div><div class=\"td_mod_wrap td-fix-index\"><div id=\"footable_parent_4645\"\n         class=\" footable_parent ninja_table_wrapper loading_ninja_table wp_table_data_press_parent bootstrap3 colored_table\">\n                        <div\n                class=\"table_description footable_description\"><h2>Improving Muscle Growth &amp; Protection<\/h2><\/div>\n                    <table data-ninja_table_instance=\"ninja_table_instance_3\" data-footable_id=\"4645\" data-filter-delay=\"1000\" aria-label=\"Improving Muscle Growth &amp; Protection\"            id=\"footable_4645\"\n           data-unique_identifier=\"ninja_table_unique_id_460894015_4645\"\n           class=\" foo-table ninja_footable foo_table_4645 ninja_table_unique_id_460894015_4645 table  ninja_search_right nt_type_legacy_table table-striped table-bordered vertical_centered ninja_custom_color inverted footable-paging-right ninja_table_search_disabled ninja_table_pro\">\n                <colgroup>\n                            <col class=\"ninja_column_0 \">\n                            <col class=\"ninja_column_1 \">\n                            <col class=\"ninja_column_2 \">\n                            <col class=\"ninja_column_3 \">\n                            <col class=\"ninja_column_4 \">\n                            <col class=\"ninja_column_5 \">\n                    <\/colgroup>\n        <thead>\n<tr class=\"footable-header\">\n                                                                                                        <th scope=\"col\"  class=\"ninja_column_0 ninja_clmn_nm_company \">Company<\/th><th scope=\"col\"  class=\"ninja_column_1 ninja_clmn_nm_drug \">Drug<\/th><th scope=\"col\"  class=\"ninja_column_2 ninja_clmn_nm_phase \">Phase<\/th><th scope=\"col\"  class=\"ninja_column_3 ninja_clmn_nm_indicationampinclusioncriteria \">Indication & Inclusion Criteria<\/th><th scope=\"col\"  class=\"ninja_column_4 ninja_clmn_nm_locations \">Locations<\/th><th scope=\"col\"  class=\"ninja_column_5 ninja_clmn_nm_clinicaltrial \">Clinical Trial<\/th><\/tr>\n<\/thead>\n<tbody>\n\n        <tr data-row_id=\"0\" class=\"ninja_table_row_0 nt_row_id_0\">\n            <td>Capricor Therapeutics<\/td><td>CAP-1002<\/td><td>Phase 3<\/td><td>10 Years and older (Child,  Adult,  Older Adult)<\/td><td>USA<\/td><td><a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.google.com\/url?q=https:\/\/clinicaltrials.gov\/study\/NCT05126758&amp;sa=D&amp;source=editors&amp;ust=1783226712713574&amp;usg=AOvVaw3nqdrr8vmTOI0iIm1NRHTD\">NCT05126758<\/a><\/td>        <\/tr>\n            <tr data-row_id=\"1\" class=\"ninja_table_row_1 nt_row_id_1\">\n            <td>Edgewise Therapeutics<\/td><td>EDG-5506<\/td><td>Phase 2<\/td><td>4 Years to 17 Years (Child)<\/td><td>USA<\/td><td><span style=\"text-decoration:underline;color:#1155cc\"><a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.google.com\/url?q=https:\/\/clinicaltrials.gov\/study\/NCT05540860&amp;sa=D&amp;source=editors&amp;ust=1783226712714143&amp;usg=AOvVaw3RoytaxCcl8O0Vp0-EWuVo\">NCT05540860<\/a><\/span><br \/><span style=\"text-decoration:underline;color:#1155cc\"><a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.google.com\/url?q=https:\/\/clinicaltrials.gov\/study\/NCT06100887&amp;sa=D&amp;source=editors&amp;ust=1783226712714282&amp;usg=AOvVaw0iPOAM4wt2zJEAdWWTQA4x\">NCT06100887<\/a><\/span><br \/><span style=\"text-decoration:underline;color:#1155cc\"><a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.google.com\/url?q=https:\/\/clinicaltrials.gov\/study\/NCT05540860&amp;sa=D&amp;source=editors&amp;ust=1783226712714353&amp;usg=AOvVaw0mNQ5D8iLRscREkir9IYl3\">NCT05540860<\/a><\/span><\/td>        <\/tr>\n            <tr data-row_id=\"2\" class=\"ninja_table_row_2 nt_row_id_2\">\n            <td>Dystrogen Therapeutics<\/td><td><a target=\"_blank\" rel=\"noreferrer\" href=\"https:\/\/www.google.com\/url?q=https:\/\/dmdwarrior.com\/significant-improvements-seen-in-3-children-receiving-dystrogen-therapeutics-dt-dec01-cell-therapy\/&amp;sa=D&amp;source=editors&amp;ust=1783226712714654&amp;usg=AOvVaw2Iz9HXd8vpvVobfAvN41L8\">DT-DEC01<\/a><\/td><td><div class=\"softmerge-inner\" style=\"width:106px;left:-3px\">Phase I and Phase II (Integrated)<\/div><\/td><td>Boys of age 5 to 18 years old (at the time of screening), diagnosed with DMD confirmed by genetic testing.\t<\/td><td>Poland<\/td><td><a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.google.com\/url?q=https:\/\/euclinicaltrials.eu\/ctis-public\/view\/2024-519004-27-00?lang%3Den&amp;sa=D&amp;source=editors&amp;ust=1783226712715072&amp;usg=AOvVaw1kCsrTaEmGvz53fx9hBn3u\">2024-519004-27-00<\/a><\/td>        <\/tr>\n            <tr data-row_id=\"3\" class=\"ninja_table_row_3 nt_row_id_3\">\n            <td>Satellos Bioscience<\/td><td>SAT-3247<\/td><td>Phase 2<\/td><td>18 Years to 40 Years (Adult)<\/td><td>Australia<\/td><td><a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.google.com\/url?q=https:\/\/clinicaltrials.gov\/study\/NCT06867107&amp;sa=D&amp;source=editors&amp;ust=1783226712715435&amp;usg=AOvVaw2-4q7Y9Wuha_PyPkndmXTW\">NCT06867107<\/a><\/td>        <\/tr>\n            <tr data-row_id=\"4\" class=\"ninja_table_row_4 nt_row_id_4\">\n            <td><a target=\"_blank\" rel=\"noreferrer\" href=\"https:\/\/www.google.com\/url?q=https:\/\/dmdwarrior.com\/satellos-sat-3247-phase-2-basecamp-clinical-trial-nct07287189\/&amp;sa=D&amp;source=editors&amp;ust=1783226712715612&amp;usg=AOvVaw0RNzWYnucd23qjc93qaGEV\">Satellos Bioscience<\/a><\/td><td>SAT-3247<\/td><td>Phase 2A<\/td><td>7 Years to 9 Years (Male Child)<\/td><td>USA, Australia, Canada, Serbia, United Kingdom<\/td><td><a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.google.com\/url?q=https:\/\/clinicaltrials.gov\/study\/NCT07287189&amp;sa=D&amp;source=editors&amp;ust=1783226712715890&amp;usg=AOvVaw2L7SHDlUX_a1mqkkRC3cTe\">NCT07287189<\/a><\/td>        <\/tr>\n            <tr data-row_id=\"5\" class=\"ninja_table_row_5 nt_row_id_5\">\n            <td>Myogenica<\/td><td>MyoPAXon<\/td><td>Phase 1<\/td><td>18 Years and older (Adult,  Older Adult )<\/td><td>USA<\/td><td><a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.google.com\/url?q=https:\/\/clinicaltrials.gov\/study\/NCT06692426&amp;sa=D&amp;source=editors&amp;ust=1783226712716195&amp;usg=AOvVaw1Fe9RjOT3PntvWKLlEm9eB\">NCT06692426<\/a><\/td>        <\/tr>\n            <tr data-row_id=\"6\" class=\"ninja_table_row_6 nt_row_id_6\">\n            <td><a target=\"_blank\" rel=\"noreferrer\" href=\"https:\/\/www.google.com\/url?q=https:\/\/dmdwarrior.com\/keros-therapeutics-announces-initial-topline-results-from-the-phase-1-clinical-trial-of-ker-065-in-healthy-volunteers\/&amp;sa=D&amp;source=editors&amp;ust=1783226712716361&amp;usg=AOvVaw0K3me7P4TJzvKw0r_fhKCM\">Keros Therapeutics<\/a><\/td><td>KER-065<\/td><td>Phase 1<\/td><td>In March 2025, the first top-line results from a Phase 1 clinical study of KER-065 in healthy volunteers were announced. KER-065 was generally well tolerated.<\/td><td>NA<\/td><td>NA<\/td>        <\/tr>\n    <\/tbody><!--ninja_tobody_rendering_done-->\n<!--ninja_cached_data-->    <\/table>\n    \n    \n    \n<\/div>\n\n<\/div><\/div><div class=\"td_block_wrap td_block_text_with_title tdi_36 tagdiv-type td-pb-border-top td_block_template_1\"  data-td-block-uid=\"tdi_36\" ><div class=\"td-block-title-wrap\"><\/div><div class=\"td_mod_wrap td-fix-index\"><div id=\"footable_parent_4647\"\n         class=\" footable_parent ninja_table_wrapper loading_ninja_table wp_table_data_press_parent bootstrap3 colored_table\">\n                        <div\n                class=\"table_description footable_description\"><h1 class=\"vm-doc-header\">MRNA - tRNA - saRNA Therapies<\/h1><\/div>\n                    <table data-ninja_table_instance=\"ninja_table_instance_4\" data-footable_id=\"4647\" data-filter-delay=\"1000\" aria-label=\"MRNA - tRNA - saRNA Therapies\"            id=\"footable_4647\"\n           data-unique_identifier=\"ninja_table_unique_id_1237048408_4647\"\n           class=\" foo-table ninja_footable foo_table_4647 ninja_table_unique_id_1237048408_4647 table  ninja_search_right nt_type_legacy_table table-striped table-bordered vertical_centered ninja_custom_color inverted footable-paging-right ninja_table_search_disabled ninja_table_pro\">\n                <colgroup>\n                            <col class=\"ninja_column_0 \">\n                            <col class=\"ninja_column_1 \">\n                            <col class=\"ninja_column_2 \">\n                            <col class=\"ninja_column_3 \">\n                            <col class=\"ninja_column_4 \">\n                            <col class=\"ninja_column_5 \">\n                    <\/colgroup>\n        <thead>\n<tr class=\"footable-header\">\n                                                                                                        <th scope=\"col\"  class=\"ninja_column_0 ninja_clmn_nm_company \">Company<\/th><th scope=\"col\"  class=\"ninja_column_1 ninja_clmn_nm_drug \">Drug<\/th><th scope=\"col\"  class=\"ninja_column_2 ninja_clmn_nm_phase \">Phase<\/th><th scope=\"col\"  class=\"ninja_column_3 ninja_clmn_nm_indicationampinclusioncriteria \">Indication & Inclusion Criteria<\/th><th scope=\"col\"  class=\"ninja_column_4 ninja_clmn_nm_locations \">Locations<\/th><th scope=\"col\"  class=\"ninja_column_5 ninja_clmn_nm_clinicaltrial \">Clinical Trial<\/th><\/tr>\n<\/thead>\n<tbody>\n\n        <tr data-row_id=\"0\" class=\"ninja_table_row_0 nt_row_id_0\">\n            <td>Ractigen Therapeutics<\/td><td><a target=\"_blank\" rel=\"noreferrer\" href=\"https:\/\/www.google.com\/url?q=https:\/\/dmdwarrior.com\/ractigen-therapeutics-study-of-rag-18-sarna-for-duchenne-muscular-dystrophy\/&amp;sa=D&amp;source=editors&amp;ust=1783226714482448&amp;usg=AOvVaw3xzhYmXDJUiSG4JHAGtmAD\">RAG-18<\/a><\/td><td>Early Phase 1<\/td><td>4 Years to 15 Years (Male Child)<\/td><td>CHINA<\/td><td><a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.google.com\/url?q=https:\/\/clinicaltrials.gov\/study\/NCT07282652&amp;sa=D&amp;source=editors&amp;ust=1783226714482640&amp;usg=AOvVaw10fS_nx9CSqWjoNYFvk0JP\">NCT07282652<\/a><\/td>        <\/tr>\n            <tr data-row_id=\"1\" class=\"ninja_table_row_1 nt_row_id_1\">\n            <td>Elixirgen Therapeutics<\/td><td><a target=\"_blank\" rel=\"noreferrer\" href=\"https:\/\/www.google.com\/url?q=https:\/\/dmdwarrior.com\/what-is-bobcat-mrna-how-does-bobcat-mrna-work-for-duchenne-muscular-dystrophy\/&amp;sa=D&amp;source=editors&amp;ust=1783226714482831&amp;usg=AOvVaw1KY1IAHK_ovxXEdlp-2m8d\">Bobcat mRNA<\/a><\/td><td>Pre-Clinical<\/td><td>NA<\/td><td>USA<\/td><td>NA<\/td>        <\/tr>\n            <tr data-row_id=\"2\" class=\"ninja_table_row_2 nt_row_id_2\">\n            <td>Tevard Biosciences<\/td><td><a target=\"_blank\" rel=\"noreferrer\" href=\"https:\/\/www.google.com\/url?q=https:\/\/dmdwarrior.com\/tevard-biosciences-presents-data-demonstrating-production-of-full-length-protein-with-trna-based-therapy-for-duchenne-muscular-dystrophy\/&amp;sa=D&amp;source=editors&amp;ust=1783226714483033&amp;usg=AOvVaw3E_mRhAi3puGsyFyV2xvd9\">suptRNA<\/a><\/td><td>Pre-Clinical<\/td><td>NA<\/td><td>USA<\/td><td>NA<\/td>        <\/tr>\n    <\/tbody><!--ninja_tobody_rendering_done-->\n<!--ninja_cached_data-->    <\/table>\n    \n    \n    \n<\/div>\n\n<\/div><\/div><div class=\"td_block_wrap td_block_text_with_title tdi_37 tagdiv-type td-pb-border-top td_block_template_1\"  data-td-block-uid=\"tdi_37\" ><div class=\"td-block-title-wrap\"><\/div><div class=\"td_mod_wrap td-fix-index\"><div id=\"footable_parent_4649\"\n         class=\" footable_parent ninja_table_wrapper loading_ninja_table wp_table_data_press_parent bootstrap3 colored_table\">\n                        <div\n                class=\"table_description footable_description\"><h1 class=\"vm-doc-header\">Gene Editing<\/h1><\/div>\n                    <table data-ninja_table_instance=\"ninja_table_instance_5\" data-footable_id=\"4649\" data-filter-delay=\"1000\" aria-label=\"Gene Editing\"            id=\"footable_4649\"\n           data-unique_identifier=\"ninja_table_unique_id_2289276004_4649\"\n           class=\" foo-table ninja_footable foo_table_4649 ninja_table_unique_id_2289276004_4649 table  ninja_search_right nt_type_legacy_table table-striped table-bordered vertical_centered ninja_custom_color inverted footable-paging-right ninja_table_search_disabled ninja_table_pro\">\n                <colgroup>\n                            <col class=\"ninja_column_0 \">\n                            <col class=\"ninja_column_1 \">\n                            <col class=\"ninja_column_2 \">\n                            <col class=\"ninja_column_3 \">\n                            <col class=\"ninja_column_4 \">\n                            <col class=\"ninja_column_5 \">\n                    <\/colgroup>\n        <thead>\n<tr class=\"footable-header\">\n                                                                                                        <th scope=\"col\"  class=\"ninja_column_0 ninja_clmn_nm_company \">Company<\/th><th scope=\"col\"  class=\"ninja_column_1 ninja_clmn_nm_drug \">Drug<\/th><th scope=\"col\"  class=\"ninja_column_2 ninja_clmn_nm_phase \">Phase<\/th><th scope=\"col\"  class=\"ninja_column_3 ninja_clmn_nm_indicationampinclusioncriteria \">Indication & Inclusion Criteria<\/th><th scope=\"col\"  class=\"ninja_column_4 ninja_clmn_nm_locations \">Locations<\/th><th scope=\"col\"  class=\"ninja_column_5 ninja_clmn_nm_clinicaltrial \">Clinical Trial<\/th><\/tr>\n<\/thead>\n<tbody>\n\n        <tr data-row_id=\"0\" class=\"ninja_table_row_0 nt_row_id_0\">\n            <td>HuidaGene<\/td><td>HG302<\/td><td>NA<\/td><td>Duchenne Muscular Dystrophy<br \/>4 Years to 8 Years<br \/>Ambulatory<br \/>Mutation in Exons 52, 52-61, or 52-63<br \/><\/td><td>China<\/td><td><a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.google.com\/url?q=https:\/\/clinicaltrials.gov\/study\/NCT06594094&amp;sa=D&amp;source=editors&amp;ust=1783226715988131&amp;usg=AOvVaw3SWo5fy4QOc2K7rXwBx1kX\">NCT06594094<\/a><\/td>        <\/tr>\n            <tr data-row_id=\"1\" class=\"ninja_table_row_1 nt_row_id_1\">\n            <td>Precision BioSciences<\/td><td>PBGENE-DMD<br \/>(Exon 45-55)<\/td><td><a target=\"_blank\" rel=\"noreferrer\" href=\"https:\/\/www.google.com\/url?q=https:\/\/dmdwarrior.com\/precision-biosciences-pbgene-dmd-phase-1-2a-function-dmd-clinical-trial-nct07429240\/&amp;sa=D&amp;source=editors&amp;ust=1783226715988514&amp;usg=AOvVaw3G04ZJmF4CPjtog19rjM20\">Phase 1\/\u200b2a<\/a><\/td><td>2 Years to 7 Years (Child)<br \/>DMD mutation should fully contained between exons 45 to 55 [inclusive]<\/td><td>NA<\/td><td><a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.google.com\/url?q=https:\/\/clinicaltrials.gov\/study\/NCT07429240&amp;sa=D&amp;source=editors&amp;ust=1783226715988747&amp;usg=AOvVaw1SzIh-XIhsKkhWc0LG8ipt\">NCT07429240<\/a><\/td>        <\/tr>\n            <tr data-row_id=\"2\" class=\"ninja_table_row_2 nt_row_id_2\">\n            <td>Vertex Pharmaceuticals<\/td><td>CRISPR\/Cas9<\/td><td>Pre-Clinical<\/td><td>NA<\/td><td>NA<\/td><td>NA<\/td>        <\/tr>\n            <tr data-row_id=\"3\" class=\"ninja_table_row_3 nt_row_id_3\">\n            <td>MyoGene Bio<\/td><td>MyoDys<br \/>(Exon 45-55)<\/td><td>Pre-Clinical<\/td><td>NA<\/td><td>NA<\/td><td>NA<\/td>        <\/tr>\n            <tr data-row_id=\"4\" class=\"ninja_table_row_4 nt_row_id_4\">\n            <td>GenAssist<\/td><td>GEN6050X<br \/>(Exon 50)<\/td><td>Pre-Clinical<\/td><td>NA<\/td><td>NA<\/td><td>NA<\/td>        <\/tr>\n    <\/tbody><!--ninja_tobody_rendering_done-->\n<!--ninja_cached_data-->    <\/table>\n    \n    \n    \n<\/div>\n\n<\/div><\/div><div class=\"td_block_wrap td_block_text_with_title tdi_38 tagdiv-type td-pb-border-top td_block_template_1\"  data-td-block-uid=\"tdi_38\" ><div class=\"td-block-title-wrap\"><\/div><div class=\"td_mod_wrap td-fix-index\"><div id=\"footable_parent_4653\"\n         class=\" footable_parent ninja_table_wrapper loading_ninja_table wp_table_data_press_parent bootstrap3 colored_table\">\n                        <div\n                class=\"table_description footable_description\"><h1 class=\"vm-doc-header\">Regulating Calcium Balance<\/h1><\/div>\n                    <table data-ninja_table_instance=\"ninja_table_instance_6\" data-footable_id=\"4653\" data-filter-delay=\"1000\" aria-label=\"Regulating Calcium Balance\"            id=\"footable_4653\"\n           data-unique_identifier=\"ninja_table_unique_id_2907737249_4653\"\n           class=\" foo-table ninja_footable foo_table_4653 ninja_table_unique_id_2907737249_4653 table  ninja_search_right nt_type_legacy_table table-striped table-bordered vertical_centered ninja_custom_color inverted footable-paging-right ninja_table_search_disabled ninja_table_pro\">\n                <colgroup>\n                            <col class=\"ninja_column_0 \">\n                            <col class=\"ninja_column_1 \">\n                            <col class=\"ninja_column_2 \">\n                            <col class=\"ninja_column_3 \">\n                            <col class=\"ninja_column_4 \">\n                            <col class=\"ninja_column_5 \">\n                    <\/colgroup>\n        <thead>\n<tr class=\"footable-header\">\n                                                                                                        <th scope=\"col\"  class=\"ninja_column_0 ninja_clmn_nm_company \">Company<\/th><th scope=\"col\"  class=\"ninja_column_1 ninja_clmn_nm_drug \">Drug<\/th><th scope=\"col\"  class=\"ninja_column_2 ninja_clmn_nm_phase \">Phase<\/th><th scope=\"col\"  class=\"ninja_column_3 ninja_clmn_nm_indicationampinclusioncriteria \">Indication & Inclusion Criteria<\/th><th scope=\"col\"  class=\"ninja_column_4 ninja_clmn_nm_locations \">Locations<\/th><th scope=\"col\"  class=\"ninja_column_5 ninja_clmn_nm_clinicaltrial \">Clinical Trial<\/th><\/tr>\n<\/thead>\n<tbody>\n\n<\/tbody><!--ninja_tobody_rendering_done-->\n<!--ninja_cached_data-->    <\/table>\n    \n    \n    \n<\/div>\n\n<\/div><\/div><div class=\"td_block_wrap td_block_text_with_title tdi_39 tagdiv-type td-pb-border-top td_block_template_1\"  data-td-block-uid=\"tdi_39\" ><div class=\"td-block-title-wrap\"><\/div><div class=\"td_mod_wrap td-fix-index\"><div id=\"footable_parent_4655\"\n         class=\" footable_parent ninja_table_wrapper loading_ninja_table wp_table_data_press_parent bootstrap3 colored_table\">\n                        <div\n                class=\"table_description footable_description\"><h1 class=\"vm-doc-header\">Improving Heart Function<\/h1><\/div>\n                    <table data-ninja_table_instance=\"ninja_table_instance_7\" data-footable_id=\"4655\" data-filter-delay=\"1000\" aria-label=\"Improving Heart Function\"            id=\"footable_4655\"\n           data-unique_identifier=\"ninja_table_unique_id_2698385799_4655\"\n           class=\" foo-table ninja_footable foo_table_4655 ninja_table_unique_id_2698385799_4655 table  ninja_search_right nt_type_legacy_table table-striped table-bordered vertical_centered ninja_custom_color inverted footable-paging-right ninja_table_search_disabled ninja_table_pro\">\n                <colgroup>\n                            <col class=\"ninja_column_0 \">\n                            <col class=\"ninja_column_1 \">\n                            <col class=\"ninja_column_2 \">\n                            <col class=\"ninja_column_3 \">\n                            <col class=\"ninja_column_4 \">\n                            <col class=\"ninja_column_5 \">\n                    <\/colgroup>\n        <thead>\n<tr class=\"footable-header\">\n                                                                                                        <th scope=\"col\"  class=\"ninja_column_0 ninja_clmn_nm_company \">Company<\/th><th scope=\"col\"  class=\"ninja_column_1 ninja_clmn_nm_drug \">Drug<\/th><th scope=\"col\"  class=\"ninja_column_2 ninja_clmn_nm_phase \">Phase<\/th><th scope=\"col\"  class=\"ninja_column_3 ninja_clmn_nm_indicationampinclusioncriteria \">Indication & Inclusion Criteria<\/th><th scope=\"col\"  class=\"ninja_column_4 ninja_clmn_nm_locations \">Locations<\/th><th scope=\"col\"  class=\"ninja_column_5 ninja_clmn_nm_clinicaltrial \">Clinical Trial<\/th><\/tr>\n<\/thead>\n<tbody>\n\n        <tr data-row_id=\"0\" class=\"ninja_table_row_0 nt_row_id_0\">\n            <td>ImmunoForge<\/td><td>Pemziviptadil<\/td><td><a target=\"_blank\" rel=\"noreferrer\" href=\"https:\/\/www.google.com\/url?q=https:\/\/dmdwarrior.com\/immunoforge-receives-fda-ind-approval-for-phase-2-clinical-trial-of-pemziviptadil-for-dmd-cardiomyopathy\/&amp;sa=D&amp;source=editors&amp;ust=1783226717152155&amp;usg=AOvVaw3dGzxC5wOqnMTl6ngCojRi\">Phase 2<\/a><\/td><td>NA<\/td><td>South Korea<\/td><td>NA<\/td>        <\/tr>\n            <tr data-row_id=\"1\" class=\"ninja_table_row_1 nt_row_id_1\">\n            <td><div class=\"softmerge-inner\" style=\"width:194px;left:-7px\">Cumberland Pharmaceuticals<\/div><\/td><td>Ifetroban<\/td><td>Phase 2<\/td><td>7 Years and older (Child,  Adult,  Older Adult)<\/td><td>USA<\/td><td><a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.google.com\/url?q=https:\/\/clinicaltrials.gov\/study\/NCT03340675&amp;sa=D&amp;source=editors&amp;ust=1783226717152750&amp;usg=AOvVaw3wtv5zT8APIA5vIb2eNbg9\">NCT03340675<\/a><\/td>        <\/tr>\n            <tr data-row_id=\"2\" class=\"ninja_table_row_2 nt_row_id_2\">\n            <td><div class=\"softmerge-inner\" style=\"width:193px;left:-6px\">Medical University of Gdansk<\/div><\/td><td>Metoprolol<\/td><td>Phase 3<\/td><td>8 Years to 17 Years (Child)<\/td><td>Poland<\/td><td><a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.google.com\/url?q=https:\/\/clinicaltrials.gov\/study\/NCT05066633&amp;sa=D&amp;source=editors&amp;ust=1783226717153136&amp;usg=AOvVaw1v5BdQf3SkferGHS8G2vwR\">NCT05066633<\/a><\/td>        <\/tr>\n            <tr data-row_id=\"3\" class=\"ninja_table_row_3 nt_row_id_3\">\n            <td>Sardocor<\/td><td><a target=\"_blank\" rel=\"noreferrer\" href=\"https:\/\/www.google.com\/url?q=https:\/\/dmdwarrior.com\/medera-cardiomyopathy-gene-therapy-trial-srd-001-for-duchenne-muscular-dystrophy\/&amp;sa=D&amp;source=editors&amp;ust=1783226717153304&amp;usg=AOvVaw0turskMnJUJGWdVOWWuYQH\">SRD-001<\/a><\/td><td>Phase 1<\/td><td>18 Years and older (Adult,  Older Adult)<br \/>Phase 2b to start soon<\/td><td>USA<\/td><td><a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.google.com\/url?q=https:\/\/clinicaltrials.gov\/study\/NCT06224660&amp;sa=D&amp;source=editors&amp;ust=1783226717153553&amp;usg=AOvVaw0nyMGoC9rI2WWEL-w-pgqA\">NCT06224660<\/a><\/td>        <\/tr>\n            <tr data-row_id=\"4\" class=\"ninja_table_row_4 nt_row_id_4\">\n            <td>Sardocor<\/td><td>SRD-003<\/td><td>Phase 1\/2a<\/td><td>Readout of Phase 1\/2a expected in mid-2026<br \/><br \/>Phase 2b\/3 to start in second half of 2026<\/td><td>NA<\/td><td>NA<\/td>        <\/tr>\n            <tr data-row_id=\"5\" class=\"ninja_table_row_5 nt_row_id_5\">\n            <td>Secretome Therapeutics<\/td><td>STM-01<\/td><td>Phase 1<\/td><td>STM-01 is currently being evaluated in a Phase 1 non-Duchenne study of adults with Heart Failure With Preserved Ejection Fraction. <\/td><td>NA<\/td><td>NA<\/td>        <\/tr>\n    <\/tbody><!--ninja_tobody_rendering_done-->\n<!--ninja_cached_data-->    <\/table>\n    \n    \n    \n<\/div>\n\n<\/div><\/div><div class=\"td_block_wrap td_block_text_with_title tdi_40 tagdiv-type td-pb-border-top td_block_template_1\"  data-td-block-uid=\"tdi_40\" ><div class=\"td-block-title-wrap\"><\/div><div class=\"td_mod_wrap td-fix-index\"><div id=\"footable_parent_4663\"\n         class=\" footable_parent ninja_table_wrapper loading_ninja_table wp_table_data_press_parent bootstrap3 colored_table\">\n                        <div\n                class=\"table_description footable_description\"><h1 class=\"vm-doc-header\">Enhancing Bone Health<\/h1><\/div>\n                    <table data-ninja_table_instance=\"ninja_table_instance_8\" data-footable_id=\"4663\" data-filter-delay=\"1000\" aria-label=\"Enhancing Bone Health\"            id=\"footable_4663\"\n           data-unique_identifier=\"ninja_table_unique_id_321386742_4663\"\n           class=\" foo-table ninja_footable foo_table_4663 ninja_table_unique_id_321386742_4663 table  ninja_search_right nt_type_legacy_table table-striped table-bordered vertical_centered ninja_custom_color inverted footable-paging-right ninja_table_search_disabled ninja_table_pro\">\n                <colgroup>\n                            <col class=\"ninja_column_0 \">\n                            <col class=\"ninja_column_1 \">\n                            <col class=\"ninja_column_2 \">\n                            <col class=\"ninja_column_3 \">\n                            <col class=\"ninja_column_4 \">\n                            <col class=\"ninja_column_5 \">\n                    <\/colgroup>\n        <thead>\n<tr class=\"footable-header\">\n                                                                                                        <th scope=\"col\"  class=\"ninja_column_0 ninja_clmn_nm_company \">Company<\/th><th scope=\"col\"  class=\"ninja_column_1 ninja_clmn_nm_drug \">Drug<\/th><th scope=\"col\"  class=\"ninja_column_2 ninja_clmn_nm_phase \">Phase<\/th><th scope=\"col\"  class=\"ninja_column_3 ninja_clmn_nm_indicationampinclusioncriteria \">Indication & Inclusion Criteria<\/th><th scope=\"col\"  class=\"ninja_column_4 ninja_clmn_nm_locations \">Locations<\/th><th scope=\"col\"  class=\"ninja_column_5 ninja_clmn_nm_clinicaltrial \">Clinical Trial<\/th><\/tr>\n<\/thead>\n<tbody>\n\n        <tr data-row_id=\"0\" class=\"ninja_table_row_0 nt_row_id_0\">\n            <td>Roche\/Genentech<\/td><td>Satralizumab<\/td><td>Phase 2<\/td><td>8 Years to 17 Years (Child)<\/td><td>USA, Italy, Poland, Spain<\/td><td><a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.google.com\/url?q=https:\/\/www.clinicaltrials.gov\/study\/NCT06450639&amp;sa=D&amp;source=editors&amp;ust=1783226719973794&amp;usg=AOvVaw0kgGN5rqVy3YKOvt47n-dK\">NCT06450639<\/a><\/td>        <\/tr>\n    <\/tbody><!--ninja_tobody_rendering_done-->\n<!--ninja_cached_data-->    <\/table>\n    \n    \n    \n<\/div>\n\n<\/div><\/div><div class=\"td_block_wrap td_block_text_with_title tdi_41 tagdiv-type td-pb-border-top td_block_template_1\"  data-td-block-uid=\"tdi_41\" ><div class=\"td-block-title-wrap\"><\/div><div class=\"td_mod_wrap td-fix-index\"><div id=\"footable_parent_4880\"\n         class=\" footable_parent ninja_table_wrapper loading_ninja_table wp_table_data_press_parent bootstrap3 colored_table\">\n                        <div\n                class=\"table_description footable_description\"><h1>Ultrasound-Mediated Delivery (UMD)<\/h1><\/div>\n                    <table data-ninja_table_instance=\"ninja_table_instance_9\" data-footable_id=\"4880\" data-filter-delay=\"1000\" aria-label=\"Ultrasound-Mediated Delivery (UMD)\"            id=\"footable_4880\"\n           data-unique_identifier=\"ninja_table_unique_id_2390648573_4880\"\n           class=\" foo-table ninja_footable foo_table_4880 ninja_table_unique_id_2390648573_4880 table  ninja_search_right nt_type_legacy_table table-striped table-bordered vertical_centered ninja_custom_color inverted footable-paging-right ninja_table_search_disabled ninja_table_pro\">\n                <colgroup>\n                            <col class=\"ninja_column_0 \">\n                            <col class=\"ninja_column_1 \">\n                            <col class=\"ninja_column_2 \">\n                            <col class=\"ninja_column_3 \">\n                            <col class=\"ninja_column_4 \">\n                            <col class=\"ninja_column_5 \">\n                    <\/colgroup>\n        <thead>\n<tr class=\"footable-header\">\n                                                                                                        <th scope=\"col\"  class=\"ninja_column_0 ninja_clmn_nm_company \">Company<\/th><th scope=\"col\"  class=\"ninja_column_1 ninja_clmn_nm_drug \">Drug<\/th><th scope=\"col\"  class=\"ninja_column_2 ninja_clmn_nm_phase \">Phase<\/th><th scope=\"col\"  class=\"ninja_column_3 ninja_clmn_nm_indicationampinclusioncriteria \">Indication & Inclusion Criteria<\/th><th scope=\"col\"  class=\"ninja_column_4 ninja_clmn_nm_locations \">Locations<\/th><th scope=\"col\"  class=\"ninja_column_5 ninja_clmn_nm_clinicaltrial \">Clinical Trial<\/th><\/tr>\n<\/thead>\n<tbody>\n\n        <tr data-row_id=\"0\" class=\"ninja_table_row_0 nt_row_id_0\">\n            <td><a target=\"_blank\" rel=\"noreferrer\" href=\"https:\/\/www.google.com\/url?q=https:\/\/dmdwarrior.com\/sonothera-ultrasound-mediated-delivery-method-can-deliver-full-length-dystrophin-to-cells\/&amp;sa=D&amp;source=editors&amp;ust=1783234135610435&amp;usg=AOvVaw1gVNtSum08ieDgt3mqrsW8\">SonoThera<\/a><\/td><td>RIPPLE<\/td><td>Pre-Clinical<\/td><td>Using ultrasound-mediated delivery (UMD), SonoThera is developing a proprietary, nonviral, non-invasive approach which enables broad, highly-targeted biodistribution, delivery of diverse genetic payloads, in a redosable manner designed to be safe, well-tolerated and cost-effective.<\/td><td>NA<\/td><td>NA<\/td>        <\/tr>\n    <\/tbody><!--ninja_tobody_rendering_done-->\n    <\/table>\n    \n    \n    \n<\/div>\n\n<\/div><\/div><div class=\"td_block_wrap td_block_text_with_title tdi_42 tagdiv-type td-pb-border-top td_block_template_1\"  data-td-block-uid=\"tdi_42\" ><div class=\"td-block-title-wrap\"><\/div><div class=\"td_mod_wrap td-fix-index\"><div id=\"footable_parent_6713\"\n         class=\" footable_parent ninja_table_wrapper loading_ninja_table wp_table_data_press_parent bootstrap3 colored_table\">\n                        <div\n                class=\"table_description footable_description\"><h1><span>Other Major Studies<\/span><\/h1><\/div>\n                    <table data-ninja_table_instance=\"ninja_table_instance_10\" data-footable_id=\"6713\" data-filter-delay=\"1000\" aria-label=\"Other Major Studies\"            id=\"footable_6713\"\n           data-unique_identifier=\"ninja_table_unique_id_1038269987_6713\"\n           class=\" foo-table ninja_footable foo_table_6713 ninja_table_unique_id_1038269987_6713 table  ninja_search_right nt_type_legacy_table table-striped table-bordered vertical_centered ninja_custom_color inverted footable-paging-right ninja_table_search_disabled ninja_table_pro\">\n                <colgroup>\n                            <col class=\"ninja_column_0 \">\n                            <col class=\"ninja_column_1 \">\n                            <col class=\"ninja_column_2 \">\n                            <col class=\"ninja_column_3 \">\n                            <col class=\"ninja_column_4 \">\n                            <col class=\"ninja_column_5 \">\n                    <\/colgroup>\n        <thead>\n<tr class=\"footable-header\">\n                                                                                                        <th scope=\"col\"  class=\"ninja_column_0 ninja_clmn_nm_company \">Company<\/th><th scope=\"col\"  class=\"ninja_column_1 ninja_clmn_nm_drug \">Drug<\/th><th scope=\"col\"  class=\"ninja_column_2 ninja_clmn_nm_phase \">Phase<\/th><th scope=\"col\"  class=\"ninja_column_3 ninja_clmn_nm_indicationampinclusioncriteria \">Indication & Inclusion Criteria<\/th><th scope=\"col\"  class=\"ninja_column_4 ninja_clmn_nm_locations \">Locations<\/th><th scope=\"col\"  class=\"ninja_column_5 ninja_clmn_nm_clinicaltrial \">Clinical Trial<\/th><\/tr>\n<\/thead>\n<tbody>\n\n        <tr data-row_id=\"0\" class=\"ninja_table_row_0 nt_row_id_0\">\n            <td>Tenaya Therapeutics<\/td><td><a target=\"_blank\" rel=\"noreferrer\" href=\"https:\/\/www.google.com\/url?q=https:\/\/dmdwarrior.com\/tenaya-tn-301-beats-givinostat-in-improving-dmd-muscle-function\/&amp;sa=D&amp;source=editors&amp;ust=1783234136637159&amp;usg=AOvVaw3EI-NCwNsEZkAfS-a5FtHK\">TN-301<\/a><\/td><td>Pre-Clinical<\/td><td>HDAC Inhibitor<\/td><td>NA<\/td><td>NA<\/td>        <\/tr>\n    <\/tbody><!--ninja_tobody_rendering_done-->\n    <\/table>\n    \n    \n    \n<\/div>\n\n<\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":3183,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-4611","page","type-page","status-publish","has-post-thumbnail"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/pages\/4611","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/comments?post=4611"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/pages\/4611\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/media\/3183"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/media?parent=4611"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}